




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/12, 405/14, 409/14, 401/14, 453/02, 487/04, A61K 31/445	A1	(11) International Publication Number: WO 97/08166 (43) International Publication Date: 6 March 1997 (06.03.97)
(21) International Application Number: PCT/IB96/01018 (22) International Filing Date: 29 August 1996 (29.08.96) (30) Priority Data: 60/003,084 31 August 1995 (31.08.95) US PCT/US96/05660 1 May 1996 (01.05.96) CA 08/663,880 14 June 1996 (14.06.96) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors: SHUE, Ho-Jane; 8 Hamilton Place, Pine Brook, NJ 07058 (US). SHIH, Neng-Yang; 1 Maple Drive, North Caldwell, NJ 07006 (US). BLYTHIN, David, J.; 487 Mountain Avenue, North Caldwell, NJ 07006 (US). CHEN, Xiao; 15 Hillwood Avenue, Edison, NJ 08820 (US). PIWINSKI, John, J.; 6 Saddle Ridge Drive, Clinton Township, Lebanon, NJ 08833 (US). MCCORMICK, Kevin, D.; 807 Cinder Road, Edison, NJ 08820 (US). (74) Agents: BOXER, Matthew et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS**(57) Abstract**

The invention relates to compounds of formula (I) wherein Z, R_c, y, m, u, Ar₂, n, X, R_{c'}, (I) and Ar₁ are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

5 BACKGROUND OF THE INVENTION

The present invention relates to a genus of compounds useful as antagonists of neurokinin receptors. In particular, these can be neurokinin-1 receptor (NK₁) antagonists. Some can also be neurokinin-1 receptor (NK₁) antagonists and neurokinin-2 receptor (NK₂) antagonists, that
10 is, NK₁ / NK₂ dual receptor antagonists. Some can also be neurokinin-2 receptor (NK₂) antagonists. Some can also be neurokinin-3 receptor (NK₃) antagonists.

Neurokinin receptors are found in the nervous system and the circulatory system and peripheral tissues of mammals, and therefore are
15 involved in a variety of biological processes. Neurokinin receptor antagonists are consequently expected to be useful in the treatment or prevention of various mammalian disease states, for example pulmonary disorders like asthma, cough, bronchospasm, chronic obstructive pulmonary diseases, and airway hyperreactivity; skin disorders and itch, for example,
20 atopic dermatitis, and cutaneous wheal and flare; neurogenic inflammation inflammatory diseases such as arthritis, migraine, nociception; CNS diseases such as anxiety, Parkinson's disease, movement disorders and psychosis; convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, and eating disorders such as food
25 intake inhibition; allergic rhinitis, neurodegenerative disorders, psoriasis, Huntington's disease, depression, and various gastrointestinal disorders such as Crohn's disease.

In particular, NK₁ receptors have been reported to be involved in microvascular leakage and mucus secretion, and NK₂ receptors have
30 been associated with smooth muscle contraction, making NK₁ and NK₂ receptor antagonists especially useful in the treatment and prevention of asthma.


Moreover, NK₃ receptor antagonists are especially useful in the treatment and prevention of asthma, inflammatory diseases and
35 conditions, such as ocular inflammation, allergic rhinitis, cutaneous wheal

and flare, psoriasis, atopic dermatitis, CNS diseases such as anxiety and Parkinson's disease.

Summary of the Invention

5

The invention relates to compounds of the formula:




10

each X is independently, O, (H,H), NR_d, or S;

n is 0 to 2; u is 0 to 2; l is 0 to 2;

m is 1, and y is 1 to 3; or m is 2, and y is 0;

and with the further proviso that no more than one R_c is other than H in the




moiety;

15

each R_c is independently H, C₁-C₆ alkyl, -(CH₂)_{n₁}-R₄ where n₁ is 1 to 6;

R_d is independently selected from the group consisting of H, C₁-C₆ alkyl, CN, OR_a, phenyl, substituted phenyl, benzyl, substituted benzyl, or allyl;

20



5

R_c is H, C_1 - C_6 alkyl or $(CH_2)_nOR_a$, with the proviso that no more than one R_c is other than H;

each R_a and R_b is independently selected from the group consisting of H, C_1 - C_6 alkyl, phenyl, substituted phenyl, benzyl, substituted benzyl,


- 10 allyl; with the proviso that when R_4 is $-N(R_b)C(=O)OR_a$, R_a is not H; or when R_a and R_b are attached to the same nitrogen, then R_a and R_b together with the nitrogen to which they are attached, form a 4 to 7 member ring;

wherein each R_1 and R_2 is independently H, C_1 - C_6 alkyl, CF_3 ,

C_2F_5 , Cl, Br, I, F, NO_2 , OR_a , CN, NR_aR_b , $-C(=O)R_a$, $-O-C(=O)R_a$,

- 15 $-O-C(=O)N(R_a)(R_b)-$, $-N(R_b)C(=O)OR_a$, $-N(R_a)C(=O)R_b$, $-C(=O)OR_a$, $-C(=O)N(R_a)(R_b)-$,
 $-S(=O)_2R_a$, $-S(=O)_2R_a$, $-SR_a$, and $-S(=O)_2NHR_a$; and where R_a is not H
 in $-S(=O)_2R_a$, $-S(=O)_2R_a$, or $-N(R_b)C(=O)OR_a$;

or when R_1 and R_2 are on adjacent carbons on a ring, they can form




wherein n' is 1 or 2;

and each R_3 is independently H, C_1 - C_6 alkyl, CF_3 , C_2F_5 , $\text{---}\overset{\text{O}}{\parallel}\text{C---}R_a$,

5 $\text{---}\overset{\text{O}}{\parallel}\text{C---}R_a$, $\text{---}\overset{\text{O}}{\parallel}\text{C---}N(R_a)R_b$, Cl, Br, I, F, OR_a , OCF_3 , or phenyl;


Ar_1 is heteroaryl or substituted heteroaryl,



10 or ;



Q is N or CH;

Ar_2 is heteroaryl or substituted heteroaryl;




15

Z is



5



$m_1 = 0-1$; $m_2 = 1-2$; n_3 is 0-4;


- 10 R_g is $-OR_a$ with the proviso that R_a is not H; aryl, substituted aryl, heteroaryl, substituted heteroaryl, $-NR_aR_b$, $-O-(CR_a,R_b)^{n_7}$ -aryl, $-O-(CR_a,R_b)^{n_7}$ -substituted aryl, $-O-(CR_a,R_b)^{n_7}$ -heteroaryl, $-O-(CR_a,R_b)^{n_7}$ -substituted heteroaryl, $-NR_a-(CR_a,R_b)^{n_7}$ -heteroaryl, $-NR_a-(CR_a,R_b)^{n_7}$ -substituted heteroaryl, $-O-(CR_a,R_b)^{n_7}$ -heterocycloalkyl, $-O-(CR_a,R_b)^{n_7}$ -substituted heterocycloalkyl, $-NR_a-(CR_a,R_b)^{n_7}$ -aryl, $-NR_a-(CR_a,R_b)^{n_7}$ -substituted heterocycloalkyl, $-NR_a-(CR_a,R_b)^{n_7}$ -aryl, $-NR_a-(CR_a,R_b)^{n_7}$ -substituted heterocycloalkyl.
- 15

substituted aryl, $-\text{NR}_a-(\text{CR}_a, \text{R}_b)_{n_7}$ -heterocycloalkyl, $-\text{NR}_a-(\text{CR}_a, \text{R}_b)_{n_7}$ -substituted heterocycloalkyl;

n_7 is 0 to 4;

each R_e and R_f is independently selected from the group consisting of H,


- 5 C_1 - C_6 alkyl, phenyl, substituted phenyl, benzyl, substituted benzyl, allyl; or R_e and R_f taken together with the carbon to which they are attached can also form a carbonyl group with the proviso that no more than one carbonyl



group is in the moiety;

n_5 is 1 to 2;


- 10 each R_5 is independently selected from the group consisting of H, OH,



C_1 - C_6 alkyl, $(\text{CH}_2)_{n_1}-\text{R}_4$ wherein n_1 is 1 to 6 with the proviso that when n_1 is 1, R_4 is not OH or NR_aR_b ; also with the proviso that when n_5 is 2, R_5 is C_1 - C_6 alkyl, and two R_5 can be attached to the nitrogen to form a quaternary salt;

15

R_6 is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl,



wherein X_3 is (H,H), O, NR_d , or S;

or R_6 is heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted

5 heterocycloalkyl, when n_3 is 0-4;

when R_e, R_f taken together with the carbon atom to which they are attached form a carbonyl group and n_3 is 1, R_6 can also be $-OR_a$ wherein R_a is not H,

or R_6 is $-NR_a, R_b$, $-O-(CR_a, R_b)_{n_7}$ -heteroaryl, $-O-(CR_a, R_b)_{n_7}$ -substituted

heteroaryl, $-O-(CR_a, R_b)_{n_7}$ -heterocycloalkyl, $-O-(CR_a, R_b)_{n_7}$ -substituted

10 heterocycloalkyl, $-O-(CR_a, R_b)_{n_7}$ -aryl, $-O-(CR_a, R_b)_{n_7}$ -substituted aryl,

$-NR_a-(CR_a, R_b)_{n_7}$ -heteroaryl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted heteroaryl,

$-NR_a-(CR_a, R_b)_{n_7}$ -aryl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted aryl, $-NR_a-(CR_a, R_b)_{n_7}$ -

heterocycloalkyl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted heterocycloalkyl, wherein R_a

15 and R_b are each independently selected from the group consisting of H

and C_1 - C_6 alkyl;

or any enantiomer thereof,

or a pharmaceutically acceptable salt thereof.

All of the variables in the above formulas such as Z, R_1 , R_2 , and R_3 ,

20 have the same meaning throughout the specification unless otherwise

specified.


Preferred compounds of the invention are compounds of formula I, wherein each X is O or (H,H) and at least one X is O.

5 Also preferred are compounds of formula I wherein both X's are O.

Also preferred are compounds of formula I wherein l is 0, m is 1, and y is 1-3.

10 Also preferred are compounds of formula I wherein n is 1 and u is 0.

Also preferred are compounds of formula I wherein Ar₁ is



wherein Q is N or CH;


each X_1 is independently O, S or NR_a ;

each X_2 is independently CH or N; and


n_4 is 0 or 1.

5


Also preferred are compounds of formula I wherein Ar_2 is



10 Also preferred are compounds of formula I wherein Z is




Also preferred are compounds of formula I wherein Z is




15

Also preferred are compounds of formula I wherein Z is







5 Also preferred are compounds of formula I wherein Z is




wherein R_g is $-OR_a$, $-NR_aR_b$, and $-O-(CR_a,R_b)^{n_7}$ -heteroaryl, with
 10 the proviso that when R_g is $O-(CR_a,R_b)^{n_7}$ -heteroaryl, R_a and R_b are
 each independently selected from the group consisting of H and C_1 - C_6 alkyl;
 n_7 is 0 to 4.


Also preferred are compounds of formula I wherein both X's are O; l is 0; m
 15 is 1; y is 1-3; n is 1; u is 0; Ar_1 is



5

 Ar_2 is


or




wherein n_4 is 0 or 1.

Z is defined in Formula I,

when R_e, R_f are H, C₁-C₆ alkyl, allyl, n_3 is 0-4 and R_6 is





5




or R_e and R_f taken together with the carbon to which they are attached form a carbonyl group, n_3 is 1 and R_6 is $-O-(CR_a, R_b)_{n_7}-L$, wherein L is

10






Also preferred are compounds of formula II




II

where in R_c is H; m_1 is 0 or 1; y is 1-3;
 Ar_1 and Ar_2 are both





5 R_6 is



or R_e and R_f taken together with the carbon to which they are attached form a carbonyl group, n_3 is 1 and R_6 is $-O-(CR_a, R_b)_{n_7}-L$, wherein L is


5






Also preferred are compounds of the invention of the formula II:

5




II

wherein Ar₁ and Ar₂ are both




5

Also preferred are compounds of the invention of the formula III:












10


wherein Ar₁ and Ar₂ are both





15 Exemplary compounds of the invention are compounds of the formulas:














or any enantiomer thereof,
or a pharmaceutically acceptable salt thereof.

5 The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I in combination with a pharmaceutically acceptable carrier.

10 The invention also relates to a method for inducing neurokinin antagonism which comprises administering a neurokinin antagonistic effective amount of a compound of formula I to a mammal in need thereof.

15 The invention also relates to a method for treating chronic airway diseases such as asthma and allergies; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, and
20 rheumatoid arthritis; migraine; central nervous system disorders such as depression, psychosis, dementia, and Alzheimer's disease; Down's syndrome; neuropathy; multiple sclerosis; ophthalmic disorders; conjunctivitis; auto immune disorders; graft rejection; systemic lupus
25 erythematosus; GI disorders such as Crohn's disease and ulcerative colitis; disorders of bladder function; circulatory disorders such as angina; Raynaud's disease; coughing and pain. In particular, the invention also relates to a method of treating asthma which comprises administering to a mammal in need of such treatment an anti-asthma effective amount of a
25 compound of formula I for such purpose.

Detailed Description of the Invention


30 As used herein the term alkyl means a straight or branched, saturated hydrocarbon chain having from 1 to 6 carbon atoms. The number of carbon atoms may be designated. For example, "C₁-C₆ alkyl" represents a straight or branched, saturated hydrocarbon having from 1 to 6 carbon atoms.


35 The term C₃-C₆ cycloalkyl means a cycloalkyl having from 3 to 6 carbon atoms, that is cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term alkenyl means means a straight or branched, saturated alkenyl having from 2 to 6 carbon atoms. The number of carbon atoms may be designated. For example, "C₂-C₆ alkenyl" represents a straight or branched alkenyl having from 1 to 6 carbon atoms.

5 The term alkynyl means a straight or branched alkynyl having from 2 to 6 carbon atoms. The number of carbon atoms may be designated. For example, "C₂-C₆ alkynyl" represents a straight or branched chain alkynyl having from 2 to 6 carbon atoms.

10 As used herein, a heavy dark line (—) denotes a chemical bond coming above the plane of the page. A dashed line (.....) denotes a chemical bond coming below the plane of the page.



As used herein, , for example, means that R₁, R₂, and R₃ can be in either of the rings of the above naphthyl moiety.

15

Asymmetric centers exist in compounds of formula I of the invention. Accordingly, compounds of formula I include stereoisomers.

All such isomeric forms and mixtures thereof are within the scope of the present invention. Unless otherwise indicated, the methods of preparation disclosed herein may result in product distributions which include all possible structural isomers, although it is understood that physiological response may vary according to stereochemical structure. The isomers may be separated by conventional means such as fractional crystallization, preparative plate or column chromatography on silica, alumina, or reversed phase supports or HPLC (high performance liquid chromatography).

20

25

Enantiomers may be separated, where appropriate, by derivatization or salt formation with an optically pure reagent, followed by separation by one of the aforementioned methods. Alternatively, enantiomers may be separated by chromatography on a chiral support.

30

The compounds of formula I can exist in unsolvated as well as solvated forms, including hydrated forms, e.g. the hemihydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as


water, ethanol, and the like are equivalent to the unsolvated forms for the purposes of the invention.

- Those compounds of formula I which contain a basic group such as $-\text{CH}_2\text{NH}_2$, form pharmaceutically acceptable salts. The preferred
- 5 pharmaceutically acceptable salts are nontoxic acid addition salts formed by adding to a suitable compound of the invention about a stoichiometric amount of a mineral acid, such as HCl, HBr, H_2SO_4 or H_3PO_4 or of an organic acid such as acetic, propionic, valeric, oleic, palmitic, stearic, lauric, benzoic, lactic, para-toluenesulfonic, methanesulfonic, citric, maleic,
- 10 fumaric, succinic and the like, respectively.

General Methods of Preparation

- The compounds of this invention may be prepared by one of
- 15 the following general methods. As used herein RT means room temperature. Unless otherwise indicated, variables in the structural formulas below are as defined above. Starting materials and reagents used in the methods and examples below, are known or may be prepared according to known methods.

- 20 As used herein the term "substituted phenyl" means



wherein R_1 , R_2 , and R_3 are as described herein.

"substituted" means substituted by R_1 , R_2 , and/or R_3 as described herein.

- "Aryl" means phenyl, naphthyl, indenyl, tetrahydronaphthyl, indanyl, anthracenyl or fluorenyl.
- 25

"Halogeno" refers to fluoro, chloro, bromo or iodo atoms.

- "Heterocycloalkyl" refers to 4- to 6-membered rings comprising 1 to 3 heteroatoms independently selected from the group consisting of $-\text{O}-$, $-\text{S}-$ and $-\text{N}(\text{R}^6)-$, with the remaining ring members being carbon. Examples
- 30 of heterocycloalkyl rings are tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl.

"Heteroaryl" refers to 5- to 10-membered single or benzofused aromatic rings comprising 1 to 3 heteroatoms independently selected from the group consisting of -O-, -S- and -N=. Examples of single-ring heteroaryl groups are pyridyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazolyl. Examples of benzofused heteroaryl groups are quinolinyl, thianaphthenyl and benzofurazanyl. N-oxides of nitrogen-containing heteroaryl groups are also included. All positional isomers are contemplated, e.g., 1-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl.

Where R² and R³ substituents form a ring and additional heteroatoms are present, the rings do not include adjacent oxygen and/or sulfur atoms or three adjacent heteroatoms. Typical rings so formed are morpholinyl, piperazinyl and piperidinyl.

As used herein, the term "BOC" means t-butoxycarbonyl.

As used herein, the term "Ph" means phenyl.

As used herein, the term "RT" means room temperature.

As used herein, the term "parallel synthesis" means the preparation of individual chemical compounds as one of a batch of, for instance, 20, 30, or even 100 identical reactions on usually a single substrate but using a different reagent in each vessel. Such reagents are always of the same general class- in this case, either carboxylic acids or organic amines in any set of parallel reactions. The conditions used for each reaction are identical to those described in the examples, except that a simplified work-up is employed, generally a simple wash either with acid or base if appropriate, then water. The presence of the product is detected by thin layer chromatography (TLC) using known products as representative standards. Further characterization by combination HPLC/MS is generally performed. No further purification is performed on these materials before they are submitted to biological assays.

As used herein, each R_C and R_{C'} is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, unsubstituted or substituted phenyl, and unsubstituted or substituted benzyl,


The starting materials in the methods below are either known or can be prepared in accordance with known methods. In particular, the following compounds are either known or can be prepared in accordance

with known methods: the diamine A, the compounds of formulas A, VI, VIII, X, XI, XIV, XVIII, XIX, XXa, A', XXV, and Z-H, as well as esters of


formula XI, and compounds of formula $\text{Ar}_2\text{---}(\text{---})_{u+1}\text{COO-alkyl}$

- Method 1.** If the group Ar_2 is an aromatic group with no I or Br substituents, then the following method may be used to prepare the useful intermediates (IV):

10




- Transition metal catalyzed coupling of 2-chloropyrazine with an aromatic Grignard reagent in a dry, ether solvent, such as THF, yields the aryl-substituted pyrazine of formula II'. The catalyst shown, [1,2-bis-(diphenylphosphino)ethane]nickel(II) chloride, is a preferred reagent for this transformation. Where Ar_2 has no halo substituents, reduction of a compound of formula II' by catalytic hydrogenation, using, for instance, palladium acetate, preferably in acetic acid solvent, results in preferential reduction of the pyrazine ring, leaving the aromatic ring unreduced, that is, it results in a compound of formula II. Similarly, 10% Pd on charcoal (Pd-C) can be used in an alcohol solvent, preferably methanol, with or without the addition of a small quantity (1 to 5 equivalents) of acetic acid. Reaction times of about 1 to 24 hours generally suffice for this reaction, which is preferentially run at room temperature or slightly above (up to about 50°C) and using from 1 to about 6 atmospheres pressure of hydrogen.




The intermediate of formula II may also be prepared from a compound of formula II', even if the group Ar_2 contains halogen atoms, by reduction using a strong hydride ion donor, preferably lithium aluminum hydride (LAH) or diisobutyl aluminum hydride (DIBAL-H) in an ether solvent, such as ether, THF or dimethoxyethane (DME).

Selective alkylation of a compound of formula II is possible using low temperature conditions. Thus, reacting a compound of formula II with a substituted aryl-alkyl halide of formula III where l is 0 to 2, results in the formation of the 4-substituted derivative of formula IV. Suitable conditions include use of a halogenated solvent, such as CH_2Cl_2 , at low temperature. Suitable temperatures are from -78°C initially, allowing the reaction mixture to warm gradually to RT if the reaction is not completed after several hours. The reaction is catalyzed by the addition of an equivalent amount of an organic base, such as triethylamine and diisopropylethylamine (Hünig's base).




Method 2. If the group Ar_2 contains one or more halogen atoms on an aromatic ring and the other groups are as in Method 1, then an alternate route to a compound of formula IV is preferred. In addition, this method can be used to prepare compounds in which l is from 0 to 2. Mono-protection of the diamine of formula (A), preferably with BOC anhydride, or other agents

known to introduce the t-butyloxycarbonyl protecting group, in an alcohol solvent, such as methanol, preferably at about -10°C, produces a compound of formula V.




- 5 These compounds are used to perform a reductive amination reaction with the aldehyde of formula VI to produce an amine of formula VII. (In structures (A), (V), (VII), and (IX) herein, R_c can be bound to any position between the two nitrogens. In cyclic structures like (IVA) below, R_c can be bound to any available cyclic position that is occupied by carbon, and that is between the two nitrogens.)
- 10


- Suitable conditions for this type of reaction include the use of an alcohol solvent, preferably methanol, or 2,2,2-trifluoroethanol, made slightly acidic with a weak organic acid, such as acetic acid, and a reducing agent known to favor reductive amination reactions, preferably
- 15 sodium cyanoborohydride, NaBH_3CN .




- Reaction of a compound of formula VII with an α -haloketone of formula VIII, in which Ar_2 preferably represents a halogenated aromatic ring, but may be any of the claimed aromatic rings, in the presence of an organic base, such as di-isopropylethylamine, also known as Hünig's Base,
- 20 in an ether solvent, such as THF, results in the formation of the intermediates of formula IX.




- 5 Removal of the BOC protecting group using a suitable acidic catalyst, such as trifluoroacetic acid, followed by an intramolecular reductive amination, under conditions such as those described above for the preparation of a compound of formula VII, leads to the formation of compounds of formula IVA.




- 10 **Method 3.** An alternate route to compounds of the invention in which *l* is 0 to 2 is as follows. Standard coupling of an N-protected amino acid of formula X, wherein Ar_2 is as described above, with an amino acid



- dipeptide of formula XII. A suitable protecting group is BOC, although many others may also be used. Other esters of the amino acid may also be used. Standard coupling techniques may be applied, an example being the use of N-hydroxybenztriazole (HOBT) and a water-soluble carbodiimide, such as 1-
- 5 (3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC), in a non-hydroxylic solvent such as CH_2Cl_2 , DMF or a mixture of the two foregoing solvents. The reaction is run, preferably, at or below RT, and takes from 1 to 40 hours for completion, depending upon the substrates.




- 10 Removal of the protecting group under standard conditions, followed by treatment of the product with a base results in cyclization to the diketopiperazine of formula XIII. Suitable conditions for removal of the exemplified BOC group are well known in the art and include catalysis by trifluoroacetic acid (TFA). A suitable base for cyclization is the
- 15 alkali metal salt of an alcohol in the alcohol itself used as solvent. For example, a solution of sodium ethoxide in ethanol may be used. The temperature is preferably around RT but may be slightly above or below, in the range 0°C to about 40°C . The reaction is generally complete within a few hours. Suitable reaction times are from 1 to 24 hours.





- 20 Reduction of the diketopiperazine of formula XIII to a compound of formula II may be accomplished preferentially with a strong hydride reducing agent, such as LAH or a solution of sodium bis(2-methoxyethoxy)aluminum hydride in toluene (also known as Red-Al®), or the
- 25 $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$ complex. Suitable solvents for this reaction are DME and

other higher boiling ethers since the reaction is run at elevated temperatures, from about 50°C to about 110°C, preferably at about 90°C.



- Alternatively, a compound of formula of II may be prepared by the scheme shown below (J. Med. Chem., 9, 191 (1966)). As used herein L is any readily available ester residue such as C₁-C₇ alkyl, more preferably methyl or ethyl.




- A compound of formula II may be converted to a compound of formula IV by the processes described in Method 1 above or Method 6 below.

- Method 4.** The intermediates of formula IV or IVA, formed via any of the previous methods, may be further processed as follows. A compound of formula IVA will be used in the Schemes. Reaction of a compound of formula IVA with an activated halo-acid, generally the acid halide of formula XIV, in which Hal represents Cl, Br, or I, yields the acylated derivative of formula XV that is, m is 1 for formula I. An organic base is used to take up the hydrogen halide formed in the reaction, suitable bases being triethylamine (TEA) and Hünig's Base. Suitable reaction media


include halogenated solvents, such as methylene chloride and chloroform. The reaction is preferably run at low temperature, at least initially. Suitable temperatures are in the region of -50°C down to -80°C . Later in the reaction it may be desirable to allow the mixture to warm up to about RT to ensure completion of the reaction.

5




Reaction of the halogenated amides of formula XV with an amine of formula Z-H results in formation of the products of formula XVI, which are compounds of the invention in which X is O and m is 1.

- 10 Compounds of formula XVI have been modified to show the fact that these products could have been prepared from compounds of formula IVA as well as from IV. Suitable solvents for this reaction are halogenated hydrocarbons, such as methylene chloride, and an organic base is present to absorb the H-Hal formed. Appropriate bases include Hünig's Base. The
- 15 reaction is performed at or around RT, a suitable temperature being generally in the range of from 0°C to 40°C . Reaction is complete within 1 to 48 hours.

**Method 5.**

Compounds of formula XVI where $y \neq 0$ may be converted to other compounds of the invention of formula XVII by reduction under controlled conditions.

5




Suitable reducing agents to effect this transformation include the borane-dimethyl sulfide complex, as well as other less selective reagents, such as LAH, (assuming that no other group reactive to LAH is present), Red-Al[®], and diborane in ether. Effective temperatures for the borane-dimethylsulfide complex to reduce compounds of formula XVI, range from RT to the reflux temperature of the solution of the reagent in THF (about 80°C).

10


Method 6. Intermediates of the formula XVIII may be selectively acylated by coupling with an acid of the formula XIX. Standard coupling techniques may be applied, an example being the use of HOBt, a water-soluble carbodiimide, such as DEC, and an organic base, such as triethylamine, in a non-hydroxylic solvent, such as CH_2Cl_2 , at a temperature

15

of about -20°C initially. The mixture may be allowed to warm to RT to complete the reaction. The product of reaction is the amide of formula XX.




- 5 Compounds of the formula XX, may be further acylated using an acid halide of formula XIV. The reaction is run, preferably at about -78°C , over a period of 1 to 12 hours, in a halogenated solvent, such as methylene chloride or similar solvent. An organic tertiary amine is used to absorb the H-Hal produced in the reaction. Suitable amines include triethylamine and Hünig's Base. As used herein Hal means Cl, Br, or I.




10

The compounds of formula XXI, that is, m is 1 in formula I, $y = 1-3$, $l = 0-2$ may be used for further reaction without isolation. Additional organic base, for instance, Hünig's Base, is added to the mixture followed by Z-H, at or around -78°C . The reaction is completed by allowing the

mixture to warm to RT overnight yielding the compounds of formula XXII after work-up and purification by standard methods.



- 5 The compounds of formula XXII, in which $y = 1-3$ may be converted to other products of formula XXIII by reduction under controlled conditions.



- 10 Suitable reducing agents to effect this transformation include the borane-methyl sulfide complex, as well as other less selective reagents, such as LAH, Red-Al[®], and diborane in ether or other unreactive solvents, such as THF. Using the borane-methyl sulfide complex in THF, at the reflux temperature of the solution, which is about 80°C, the reaction is complete in about 2 hours to 48 hours depending on the precise substrate.

- 15 Some of the substrates Z-H for the alkylation reaction were synthesized from diamino compound (A) by initial conversion to the t-BOC protected derivative(B) followed by removal of the benzyl group by hydrogenolysis over a suitable catalyst such as Pd(OH)₂ to yield the t-BOC


protected derivative (C). Subsequent elaboration of (C) can be accomplished by either alkylation or reductive alkylation depending on the availability of reagents for these reactions.

- 5 Reaction of the intermediate (C) with an aldehyde or ketone (D) under the conditions of reductive amination, such as in methanol and in the presence of NaBH_3CN with sufficient AcOH (acetic acid) present to allow the reaction to proceed at a suitable rate, produces the amine (E) from which the t-BOC group may be removed with 4N-HCl in dioxane followed by
10 basification, for instance, with an aqueous solution of NaOH , to produce the compound of formula (F).

- The same product, (Ea), may be prepared from (C) by alkylation with the halide derivative (G) in which "Hal" is Cl, Br, or I. Other activated leaving groups are also possible for this reagent, such as
15 mesylates or tosylates. The reagent is preferably primary but the reaction can also often be made to work acceptably for secondary derivatives.


- The product of the alkylation, (Ea), may be treated as described above to produce the reagent (Fa) which represents one of the preferred forms of Z which can be used to convert a compound of formula
20 XXI to a compound of formula XXII.

- The intermediate (C) (below) may also be modified by acylation, for instance with an acid halide of formula (H), to produce the intermediate (I), in which $n_3 \neq 0$. Removal of the BOC protecting group, as described previously, leads to the amine (J) which represents one of the
25 preferred forms of Z. This may be used to convert a compound of formula (XXI) to a compound of the invention, as described above.




Method 6a A useful intermediate for certain variations in the group Z is the compound (K). This may be prepared from (XXI) and the protected amine (L). The starting material for this process is the N-BOC protected amine (M) which may be converted to (L) by standard techniques involving formation of the oxime using hydroxylamine hydrochloride in pyridine

followed by reduction with hydrogen over Raney nickel in ethanol solution. Removal of the protecting group from (K), under conditions described previously, results in the amine (N).




- 5 Use of this intermediate under conditions of acylation, under controlled conditions, results in reaction at the ring nitrogen atom to yield products such as (O). Either the acid halide, e.g. chloride (P), may be used, or a coupling reaction with a carboxylic acid may be used under conditions essentially similar to those described earlier using a water-soluble carbodiimide reagent, for instance.
- 10

Sometimes the starting material (N) is provided as a salt, such as the HCl salt. In this case, it is necessary to add an organic tertiary base, such as Hünig's base to produce the free amine.



Alkylation of (N) may be accomplished with a suitable halogen-containing reagent, for instance, to produce (Q). Reagents such as (G)

5 may be used for this conversion.




In some cases, one of the $-\text{C}(\text{R}_\text{e})(\text{R}_\text{f})-$ groups may be a carbonyl group with the exception that the carbon in the carbonyl can not be directly attached to the nitrogen atom since these products are amides which are described above.

10


Under certain circumstances, specifically where at least one of the groups R_e and R_f on the carbon atom to be directly attached to the ring

nitrogen is H, then a reductive alkylation reaction may be performed, as described previously, to produce the compound of the invention (R). The reagent used for this conversion is (D), an aldehyde (if Re = H) or ketone.



5

Method 7. The acylated derivatives of formula XX from Method 6 may be reduced to the saturated alkyl chain derivatives of formula IVA.




10


The process to conduct this conversion is the same as described in Method 6 for conversion of a compound of formula XXII to a compound of formula XXIII. The reagent of preference is the borane-methyl sulfide complex.


15 A compound of formula IVA can be converted to a target compound of formula XVI as described previously.

- 5 An alternate route to compounds of structure (XXII) also starts with compound (XVIII). Initial reaction with an amine protecting group reagent, preferably BOC anhydride, produces the N-t-butyloxycarbonyl derivative of the formula XXVIII.



- As before, reaction occurs preferentially at the nitrogen atom further away from the Ar_2 group. Reaction of this intermediate with a reagent of structure (XIV) as described above, leads to the halo-derivative (XXIX).
- 10 Reaction of (XXIX) with Z-H, again as described above, produces the intermediate (XXX) which may be de-protected to produce (XXXI). Suitable reagents include trifluoroacetic acid and HCl.






Reaction of (XXXI) with a carboxylic acid (XIX) under such coupling conditions as described above, leads to the products of formula (XXII).

Method 7a.

- 5 Synthesis of the compounds of the invention wherein the pendant aromatic group Ar₂, or the pendant aromatic group Ar₂ and its sidechain, are located in the alternate ring position to the compounds of formula XXII (i.e. compounds of formula C below), may be prepared using compounds of formula XXVIII from method 7 as starting materials. Coupling of

- 10 compounds of formula XXVIII with any of the acids $\text{Ar}_1-\text{CH(Rc)}_n\text{CO}_2\text{H}$ under standard coupling conditions, for instance using HOBT, Et₃N and DEC in CH₂Cl₂, produces the intermediate (A). Removal of the t-BOC or other protecting group under standard conditions releases the free amine (B). Acylation of (B) and further reaction with Z-H proceeds as described in
- 15 Method 6 for the conversion of (XX) via (XXI) to (XXII) to produce compound (C) of the invention.






Method 8.

- A method for introducing a group, Rc , into the sidechain of a compound of the invention begins with a previously prepared compound of formula (XX). This may be coupled with a suitably protected amino-acid derivative of formula (XXXII) in which the t-BOC group is used as a representative protecting group. Use of a relatively reactive coupling agent, such as BOP-Cl of formula (XXXIII), is preferred and the reaction is run under standard coupling conditions well known to one skilled in the art.
- 5 Suitable conditions include the use of CH_2Cl_2 and/or DMF as solvent, with triethylamine or Hünig's Base, and a temperature between 0°C initially and RT. Usual work-up conditions yield the protected intermediate of formula (XXXIV).
- 10

- In the case of (XXXIV), in which the N-protecting group is t-BOC , the usual conditions for removal of such a group may be used to free the amine function. Various concentrations of $\text{CF}_3\text{CO}_2\text{H}$ in CH_2Cl_2 will usually suffice. In some substrates a fairly dilute solution (e.g. 2N) will be
- 15


- sufficient whereas in other cases a more concentrated solution, up to neat TFA, may be necessary. In addition, other N-protecting groups may be employed and removed by methods well known in the art. An example is use of the N-Cbz which may be removed under either acidic or
- 5 hydrogenolytic conditions. The result of deprotection is the amine intermediate of the formula (XXXV).



Conversion of intermediate of the formula (XXXV) to compounds of the invention is then carried out by a reductive alkylation process.


The group Z is introduced into the molecule using an aldehyde or ketone in which the aforementioned group is present at the carbon atom that is to be joined to the amino group of the formula (XXXV). An example of such an intermediate is a compound of the formula (XXXVI).

5



After the reaction this group becomes the Z group of the compounds of the invention, that is, the "Y-NH" group shown in compounds of the formula (XXXVII) just below

10



15 is equivalent to the "Z" group shown in the Summary of the Invention. Conditions for this reductive amination procedure are known in the art and are exemplified by the use of NaBH₃CN in MeOH with the addition of several equivalents of acetic acid. Generally, the reaction is performed at RT and is left to react overnight.

20

Product is isolated by standard means, such as decomposition of excess reagent with H₂O and extraction of the product into an organic solvent such as CH₂Cl₂ or a mixture of Et₂O and CH₂Cl₂.

5 Using procedures similar to those described in the above or using procedures known to those skilled in the art, one can produce all of the compounds of formula I of the invention. For example, one can obtain compounds of the invention of formula I wherein the R_C moiety is on various carbons of the piperazine ring.

10

The *in vitro* and *in vivo* activity of the compounds of formula I can be determined by the following procedures.

15

In vitro procedure to identify NK₁ activity

Test compounds are evaluated for their ability to inhibit the activity of the NK₁ agonist Substance P on the isolated guinea pig vas deferens. Freshly cut vas deferens are removed from male Hartley guinea pigs (230-350g) and suspended in 25 ml tissue baths containing Krebs's Henseleit solution warmed to 37°C and constantly aerated with 95% O₂ and 5% CO₂. Tissues are adjusted to 0.5 g and allowed to equilibrate for a period of 30 minutes. The vas deferens are exposed to an electrical field stimulation (Grass S48 Stimulator) every 60 seconds at an intensity that will cause the tissue to contract 80% of its maximum capacity. All responses are recorded isometrically by means of a Grass force displacement transducer (FT03) and Harvard electronic recorder. Substance P inhibits the electrical field stimulated-induced contractions of the guinea pig vas deferens. In unpaired studies, all tissues (control or drug treated) are exposed to cumulative concentrations of Substance P (1X10⁻¹⁰ M - 7X10⁻⁷ M). Single log-concentrations of the test compounds are given to separate tissues and allowed to equilibrate for 30 minutes before a Substance P concentration-response curve is generated. At least 5 separate tissues are used for each control and individual drug-concentration for every drug assay.

Inhibition of the Substance P is demonstrated by a rightward shift of its concentration-response curve. These shifts are used to determine the pA_2 value, which is defined as the negative log of the molar concentration of the inhibitor which would require that twice as much agonist
5 be used to elicit a chosen response. This value is used to determine relative antagonist potency.

10

Isolated Hamster Trachea NK₂ Assay

General methodology and characterization of hamster trachea
15 responses to neurokinin agonists as providing an NK₂ monoreceptor assay is found in C.A. Maggi, et al., *Eur. J. Pharmacol.* 166 (1989) 435 and J.L. Ellis, et al., *J. Pharm. Exp. Ther.* 267 (1993) 95.

Continuous isometric tension monitoring is achieved with
20 Grass FT-03 force displacement transducers connected to Buxco Electronics preamplifiers built into a Graphtec Linearcorder Model WR 3310.

Male Charles River LAK:LVG (SYR) hamsters, 100-200 g fed weight, are stunned by a sharp blow to the head, loss of corneal reflex is
25 assured, the hamsters are sacrificed by thoractomy and cutting the heart. Cervical trachea segments are removed to room temperature Krebs buffer, pH 7.4, aerated with 95% O₂ - 5% CO₂ gas and cleaned of adhering tissue. The segments are cut into two 3-4 mm long ring segments. Tracheal rings are suspended from transducers and anchored in 15.0 ml water jacketed
30 organ baths by means of stainless steel hooks and 6-0 silk. Baths are filled with Krebs buffer, pH 7.4, maintained at 37°C and continuously aerated with 95% O₂ - 5% CO₂ gas. Tracheal rings are placed under 1.0 g initial tension and allowed a 90 min equilibration period with four 1 μ M NKA challenge, wash and recovery cycles at 20 min intervals. 30 min vehicle pretreatment
35 is followed by cumulative additions of rising doses of NKA (3 nM - 1 μ M final concentration, 5 min intervals between additions). The final NKA response

is followed by a 15 min wash and recovery period. 30 min pretreatment with a test compound or its vehicle is followed by cumulative additions of rising doses of NKA (3 nM - 10 μ M final concentration if necessary, 5 minutes intervals between additions). The final NKA response is followed by a 1 mM
5 carbachol challenge to obtain a maximal tension response in each tissue.

Tissue responses to NKA are recorded as positive pen displacements over baseline and converted to grams tension by comparison to standard weights. Responses are normalized as a % of the maximal
10 tissue tension. ED₅₀'s are calculated for NKA from the control and treated NKA dose responses and compared. Test compounds resulting in an agonist dose ratio ≥ 2 at a screening concentration of 1 μ M (i.e. $pA_{2\geq} = 6.0$) are considered actives. Further dose response data is obtained for actives so that an apparent pA_2 estimate can be calculated. pA_2 is calculated either
15 by estimation of K_i as described by Furchgott (where $pA_2 = -\text{Log } K_i$, R.F. Furchgott, *Pharm. Rev.* 7 [1995] 183) or by Schild Plot Analysis (O. Arunlakshana & H.O. Schild, *Br. J. Pharmacol.* 14[1959] 48) if the data is sufficient.

20

Effect of NK₁ Antagonists on Substance P-Induced Airway Microvascular Leakage in Guinea Pigs

Studies are performed on male Hartley guinea pigs ranging in
25 weight from 400-650 g. The animals are given food and water *ad libitum*. The animals are anesthetized by intraperitoneal injection of dialurethane (containing 0.1 g/ml diallylbarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). The trachea is cannulated just below the larynx and the animals are ventilated ($V_T = 4$ ml, $f = 45$ breaths/min) with a Harvard rodent
30 respirator. The jugular vein is cannulated for the injection of drugs.

The Evans blue dye technique (Danko, G. et al., Pharmacol. Commun., 1, 203-209, 1992) is used to measure airway microvascular leakage (AML). Evans blue (30 mg/kg) is injected intravenously, followed 1 min later by i.v. injection of substance P (10 μ g/kg). Five min later, the
35 thorax is opened and a blunt-ended 13-gauge needle passed into the aorta. An incision is made in the right atrium and blood is expelled by

flushing 100 ml of saline through the aortic catheter. The lungs and trachea are removed en-bloc and the trachea and bronchi are then blotted dry with filter paper and weighed. Evans blue is extracted by incubation of the tissue at 37°C for 18 hr in 2 ml of formamide in stoppered tubes. The absorbance of the formamide extracts of dye is measured at 620 nm. The amount of dye is calculated by interpolation from a standard curve of Evans blue in the range 0.5-10 µg/ml in formamide. The dye concentration is expressed as ng dye per mg tissue wet weight. Test compounds were suspended in cyclodextran vehicle and given i.v. 5 min before substance P.

10

Measurement of NK₂ Activity In Vivo

Male Hartley guinea pigs (400-500 gm) with ad lib. access to food and water are anesthetized with an intraperitoneal injection of 0.9 ml/kg dialurethane (containing 0.1 g/m diallylbarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). After induction of a surgical plane of anesthesia, tracheal, esophageal and jugular venous cannulae are implanted to facilitate mechanical respiration, measurement of esophageal pressure and administration of drugs, respectively.

The guinea pigs are placed inside a whole body plethysmograph and the catheters connected to outlet ports in the plethysmograph wall. Airflow is measured using a differential pressure transducer (Validyne, Northridge CA, model MP45-1, range ± 2 cmH₂O) which measures the pressure across a wire mesh screen that covers a 1 inch hole in the wall of the plethysmograph. The airflow signal is electrically integrated to a signal proportional to volume. Transpulmonary pressure is measured as the pressure difference between the trachea and the esophagus using a differential pressure transducer (Validyne, Northridge, CA, model MP45-1, range ± 20 cm H₂O). The volume, airflow and transpulmonary pressure signals are monitored by means of a pulmonary analysis computer (Buxco Electronics, Sharon, CT, model 6) and used for the derivation of pulmonary resistance (R_L) and dynamic lung compliance (C_{Dyn}).

Bronchoconstriction Due to NKA

Increasing iv doses of NKA are administered at half log (0.01-3 µg/kg) intervals allowing recovery to baseline pulmonary mechanics

between each dose. Peak bronchoconstriction occurs within 30 seconds after each dose of agonist. The dose response is stopped when C_{Dyn} is reduced 80-90% from baseline. One dose-response to NKA is performed in each animal. Test compounds are suspended in cyclodextran vehicle and given i.v. 5 min before the initiation of the NKA dose response.

For each animal, dose response curves to NKA are constructed by plotting the percent increase in R_L or decrease in C_{Dyn} against log dose of agonist. The doses of NKA that increased R_L by 100% (R_L100) or decreased C_{Dyn} by 40% ($C_{Dyn}40$) from baseline values are obtained by log-linear interpolation of the dose response curves.

Neurokinin Receptor Binding Assay(s)

Chinese Hamster ovary (CHO) cells transfected with the coding regions for the human neurokinin 1 (NK_1) or the human neurokinin 2 (NK_2) receptors are grown in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum, 0.1 mM non-essential amino acids, 2 mM glutamine, 100units/ml of penicillin and streptomycin, and 0.8 mg of G418/ml at 37°C in a humidified atmosphere containing 5% CO_2 .

Cells are detached from T-175 flasks with a sterile solution containing 5mM EDTA in phosphate buffered saline. Cells are harvested by centrifugation and washed in RPMI media at 40°C for 5 minutes. The pellet is resuspended in Tris-HCl (pH7.4) containing 1 uM phosphoramidon and 4 ug/ml of chymostatin at a cell density of 30×10^6 cells/ml. The suspension is then homogenized in a Brinkman Polytron (setting 5) for 30-45 seconds. The homogenate is centrifuged at $800 \times g$ for 5 min at 4°C to collect unbroken cells and nuclei. The supernatant is centrifuged in a Sorvall RC5C at 19,000 rpm ($44,00 \times g$) for 30 min at 4°C. The pellet is resuspended, an aliquot is removed for a protein determination (BCA) and washed again. The resulting pellet is stored at -80°C.

To assay receptor binding, 50 μ l of [3H]-Substance P (9-Sar, 11-Met [02]) (specific activity 41 Ci/mmol) (Dupont-NEN) (0.8 nM for the NK_1 assay) or [3H]-Neurokinin A (specific activity 114 Ci/ mmole) (Zenca) (1.0 nM for the NK_2 assay) is added to tubes containing buffer (50 mM Tris-HCl (pH 7.4) with 1 mM $MnCl_2$ and 0.2% Bovine Serum Albumin) and either DMSO or test compound. Binding is initiated by the addition of 100 μ l of membrane (10-20 μ g) containing the human NK_1 or NK_2 receptor in a final volume of 200 μ l. After 40 minutes at room temperature, the reaction is

stopped by rapid filtration onto Whatman GF/C filters which have been presoaked in 0.3% polyethylenimine. Filters are washed 2 times with 3 ml of 50 mM Tris-HCl (pH7.4). Filters are added to 6 mls of Ready-Safe liquid scintillation cocktail and quantified by liquid scintillation spectrometry in a
5 LKB 1219 RackBeta counter. Non-specific binding is determined by the addition of either 1 μ M of CP-99994 (NK₁) or 1 μ M SR-48968 (NK₂) (both synthesized by the chemistry department of Schering-Plough Research Institute). IC₅₀ values are determined from competition binding curves and K_i values are determined according to Cheng and Prusoff using the
10 experimentally determined value of 0.8 nM for the NK₁ receptor and 2.4 nM for the NK₂ receptor.

For all of the compounds of the invention, the NK₁ binding is in a range of about 0-100 % inhibition at 1 μ M concentration. For all of the
15 compounds of the invention, the NK₂ binding is in a range of about 0-100 % inhibition at 1 μ M concentration. It should be understood that while the NK binding for certain compounds of the invention is as low as 0% at 1 μ M concentration, that at higher concentrations these compounds are expected to have NK binding inhibition activity.

20 The K_i of a compound is that concentration at which the compound caused 50% inhibition of either NK₁ or NK₂. For those compounds of the invention having higher than 50% inhibition of NK₁, K_i's for NK₁ were determined. The K_i's for NK₁ for such compounds fell within a range of
25 about 0.1 nM to about 1 μ M.

For those compounds of the invention having higher than 50% inhibition of NK₂, K_i's for NK₂ were determined. The K_i's for NK₂ for such compounds fell within a range of about 0.1 nM to about 1 μ M.

30 Compounds of formula I exhibit NK₁ and NK₂ antagonist activity to varying degrees, i.e., certain compounds have strong NK₁ antagonist activity, but weaker NK₂ antagonist activity. Others are strong NK₂ antagonists, but weaker NK₁ antagonists. Certain compounds have both strong NK₁ and NK₂ antagonist activities. Some compounds can also be NK₃ antagonists.

35 Many compounds of formula I have an asymmetric center and therefore exist as a pair of enantiomers. In such cases, one enantiomer can

have different biological activity than the other. For example, one enantiomer can have strong NK₁ activity and weak NK₂ activity while the other enantiomer has weak NK₁ activity and strong NK₂ activity.

5 Certain compounds of formula I have been found to be antagonists of both NK₁ and NK₂ receptors, and are therefore useful in treating conditions caused or aggravated by the activity of NK₁ and NK₂ receptors.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. Compounds of this invention can be administered in conventional
10 oral dosage forms such as capsules, tablets, powders, cachets, suspensions or solutions, or in injectable dosage forms such as solutions, suspensions, or powders for reconstitution. The pharmaceutical compositions can be prepared with conventional excipients and additives, using well known formulation techniques. Pharmaceutically acceptable
15 excipients and additives include nontoxic and chemically compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.

The daily dose of a compound of formula I for treating asthma, cough, bronchospasm, inflammatory disease, migraine, nociception and
20 gastrointestinal disorders is about 0.1 mg to about 20 mg/kg of body weight per day, preferably about 0.5 to about 15 mg/kg, more preferably 0.5 to about 5 mg/kg. For an average body weight of 70 kg, the dosage range is therefore from about 1 to about 1500 mg of drug per day, preferably about 50 to about 100 mg, given in a single dose or 2-4 divided doses. The exact
25 dose, however is determined by the attending clinician, and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

The invention disclosed herein is exemplified by the following examples, which should not be construed to limit the scope of the
30 disclosure. Alternative mechanistic pathways and analogous structures within the scope of the invention will be apparent to those skilled in the art.

EXAMPLE 1

Preparation of


2-(3,4-dichlorophenyl)piperazine

A. Synthesis of racemic compound

5

2-(3,4-Dichlorophenyl)piperazine was synthesized according to the method published in J.Med.Chem. 9,191,1966.

A. General method for the synthesis of 2-aryl-piperazine derivatives.



R_1 = Cl, H or other substituents i.e. OCH_3 , CF_3 , Br, I, F, etc.

R_2 = Cl, H or other substituents i.e. OCH_3 , CF_3 , Br, I, F, etc.

10

B. Resolution of 2-(3,4-dichlorophenyl)piperazine

Step 1

15 A solution of 2-(3,4-dichlorophenyl)piperazine (36.05 g, 0.156 mol) in methanol (200 mL) was treated with a solution containing two equivalents of N-acetyl-L-leucine (54.02 g, 0.312 mol) and heated until all of the material was dissolved. EtOAc (2.2 L) was added to this solution and allowed to stand at ambient temperature overnight. The solvent phase was decanted

20 from the precipitated salt and concentrated in vacuo. This procedure was repeated using 37.88 g of 2-(3,4-dichlorophenyl)piperazine (0.164 mol) and 56.68 g of N-acetyl-L-leucine (0.327 mol).

Step 2

The concentrated salts from both solvent phases in step 1 were combined and heated in methanol (550 mL) until all of the material dissolved. EtOAc (2.75 L) was added to this solution and allowed to stand at ambient temperature overnight. The solvent phase was decanted from the precipitated salt and concentrated in vacuo to give ~95 g of piperazine salt (72% ee of enantiomer A).

Step 3

The salt from the solvent phase in step 2 was dissolved in a solution of H₂O (800 mL) and aq. ammonia (400 mL) and extracted with CH₂Cl₂ (4 x 400 mL). The combined organic layers were dried with MgSO₄ and concentrated to give 37 g of the piperazine free base. The free base was recrystallized three times from hexane (890, 600 and 450 mL) to give 16 g of piperazine (>99.9% ee of enantiomer A).

24.7°C
[α]_D = -45.0° (MeOH)

Step 4

The precipitated salts from step 1 were combined and heated in methanol (220 mL) until all of the material dissolved. EtOAc (2.2 L) was added to this solution and allowed to stand at ambient temperature overnight. The solvent phase was decanted from the precipitated salt and dried in vacuo to give ~43 g of piperazine salt (93% ee of enantiomer B).

Step 5

A 12.3 g portion of salt (75% ee of enantiomer B) prepared by an analogous procedure to that in step 4 was dissolved in 0.5 M NaOH (400 mL) and extracted with CH₂Cl₂ (4 x 155 mL). The combined organic layers were dried with MgSO₄ and concentrated to give 3.72 g of the piperazine free base. The free base was recrystallized twice from hexane (90 and 70 mL) to give 2.1 g of piperazine (98% ee of enantiomer B).

C. Analytical procedure for measuring piperazine enantiomeric purity.

The enantiomeric purity of the piperazine was measured by chiral HPLC analysis of the di-tert-butoxycarbonyl piperazine derivative. The di-tert-butoxycarbonyl derivative was prepared by adding a small piperazine sample (free base or salt) (~.2 mg) to di-tert-butyl dicarbonate (~ 1 mg) and methanol (0.5 mL) and heating at 80°C for 1 h. If the piperazine sample is a salt, triethylamine (20 µL) is also added. The derivative was analyzed by HPLC using a ChiralPak AD column eluting with 95:5 hexane-isopropyl alcohol.


10

EXAMPLE 2

Preparation of

(+,-)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine

15



To a cooled solution of CH₂Cl₂ (600 mL) containing 2-(3,4-dichlorophenyl)piperazine (6.934 g, 30 mmol), 3,5-dimethylbenzoic acid (4.55 g, 30 mmol), and N-hydroxybenzotriazole monohydrate (4.05 g, 30 mmol) at -20 °C were added Et₃N (4.2 mL, 30 mmol) and N,N-dimethylaminopropylethylcarbodiimide (DEC) (5.86 g, 30 mmol) under nitrogen. The reaction was kept at -20 °C for an hour and gradually warmed to RT overnight. After stirring 22 hours, the reaction was complete and CH₂Cl₂ (200 mL) was added. The organic solution was washed with brine (150 mL, 3x), dried over MgSO₄, filtered and concentrated under vacuum to give 8.2 g of crude product. The product was crystallized from CH₂Cl₂/Hexane to give a light yellow solid (6.3 g, 17.34 mmol, 57.8%), m.p.139-141 °C; FAB MS [M+]⁺ 35³⁵Cl 363.1.


30

EXAMPLE 3

Preparation of

(+,-)-bromoacetyl-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine

5



To a cooled solution of (+,-)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (11.5 g, 31.65 mmol) in CH_2Cl_2 (200 mL) at 0 °C was added Hünig's base (4.5 g, 35 mmol) and bromoacetyl bromide (6.4 g, 31.65 mmol). The solution was stirred at 0 °C overnight under N_2 . After completion the reaction was diluted with CH_2Cl_2 (400 mL) and washed with brine (300 mL, 2x), dried over MgSO_4 , filtered and concentrated. The crude material was purified by flash grade silica gel chromatography, eluting with 2% $[\text{NH}_4\text{OH}/\text{MeOH} (1:9)] / 98\% \text{CH}_2\text{Cl}_2$ to give the title compound as a light yellow solid (7.1 g, 47.3%), m.p. 77-79 °C, FAB MS $[\text{M}+1]^+ \text{ } ^{35}\text{Cl}, ^{79}\text{Br}$ 482.9, 484.9.


15

EXAMPLE 4

Preparation of

(+)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (Enantiomer B)

20



The title compound was prepared by an analogous method to that described in Example 2 using (-)-2-(3,4-dichlorophenyl)piperazine in place of (+,-)-

2-(3,4-dichlorophenyl)piperazine, m.p. 97-100 °C; FAB MS [M+1]⁺ + ³⁵Cl 363.1;


$[\alpha]_D^{22.5} = +87.2^{\circ}(\text{MeOH})$.

EXAMPLE 5

Preparation of

5

(-)-bromoacetyl-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine
(Enantiomer B)



10

The title compound was prepared by an analogous method to that described in Example 3 using (+)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (Enantiomer B) (Example 4) in place of (+,-)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine, m.p. 68-71 °C, FAB MS

15 [M+1]⁺ + ³⁵Cl ⁷⁹Br 482.9, 484.8; $[\alpha]_D^{21.9} = -45.6^{\circ}(\text{MeOH})$.


EXAMPLE 6

Preparation of


(+,-)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-[1-oxo-2-phenyl)ethyl]-4-piperidiny]amino]acetyl]piperazine

20

Step 1. To a solution of 4-amino-1-benzylpiperidine (9.5 g, 50mmol) in methanol (150 mL) at -10°C was added a solution of di-*t*-butyldicarbonate (10.9 g, 50 mmol) in methanol (60 mL). The mixture was gradually warmed to room temperature overnight. After the reaction was complete, solvent was removed to give a white solid 2, FAB MS [M+1]⁺ + ³⁵Cl 291.3



Step 2. To a solution of compound **2** (11.6 g, 40 mmol) in methanol (140 mL) was added Pd(OH)₂ (20% on carbon) (2.4 g) and hydrogenolyzed at 47 psi. After the reaction was complete, the catalyst was filtered off. The filtrate was evaporated to give compound **3** (8 g, 40 mmol) as a white solid.



Step 3. Compound 3 (0.69 g, 3 mmol) was mixed with phenylacetyl chloride (0.46 g, 3 mmol) and Hünig's base (0.43 g, 3.3 mol) in CH₂Cl₂ (10 mL) at -5 °C and the solution was gradually warmed to RT overnight. After completion the reaction was diluted with CH₂Cl₂ (50 mL) and washed with brine (30 mL, 3x). The CH₂Cl₂ layer was dried over MgSO₄, filtered, and concentrated to give compound 4) as a white solid (0.81 g).

15 Step 4. This crude material was dissolved in dry CH_2Cl_2 (3 mL) and treated with 4N HCl-dioxane (6 mL). After stirring at RT for 2 h, solvents were evaporated to give 4-amino-1-(1-oxo-2-phenylethyl)piperidine **5** (0.8 g) as a white solid HCl salt. FAB MS $[\text{M}+1]^+$ 219.

Step 5. To a solution of compound 5 (0.31 g, 1.2 mmol) in CH₂Cl₂ (10 mL) was added Hünig's base (0.62 g, 4.8 mmol) followed by the addition of compound 6 (0.3 g, 0.6 mmol) (prepared in Example 3). The mixture was stirred

at RT for 5 days under N₂. After completion the reaction was diluted with CH₂Cl₂ (50 mL) and washed with brine (30 mL x2), dried over MgSO₄, filtered and concentrated to give a brown gummy crude material (0.56 g). This crude material was purified by silica gel chromatography on flash grade silica (60 g),
 5 eluting with 5% [NH₄OH / MeOH (1:9)] / 95% CH₂Cl₂ to give the title compound as a white solid (0.28 g, 0.45 mmol) in 75% of yield.


FAB MS [M+1]⁺ ³⁵Cl 621.1; m.p. 87-89 °C.

EXAMPLE 7

Preparation of

10

(+,-)-1,1-dimethylethyl-4-[[2-[2-(3,4-dichlorophenyl)-1-(3,5-dimethylbenzoyl)-1-piperaziny]-2-oxoethyl]amino]-1-piperidinecarboxylate



To a solution of N-t-butoxycarbonyl-4-piperidone 1 (15 g, 75.3 mmol) in pyridine (50 mL) was added hydroxylamine • HCl (5.23 g, 75.3 mmol). The mixture was heated in an oil bath at 65 °C for one hour. After cooling, pyridine was removed under reduced pressure and the residue was dried under high vacuum overnight to give a solid. To this solid was added water (100 mL) and the mixture was sonicated. The precipitate was filtered and washed with
 20 water then dried under high vacuum to give the oxime derivative of compound 1 (10.5 g, 65%). FAB MS [M+1]⁺ 215.3. The oxime compound (10 g, 46.67 mmol) was dissolved in absolute EtOH (100 mL) followed by the addition of Raney Ni (29 g, washed with absolute EtOH). The mixture was hydrogenated in a Parr shaker at 50 psi overnight. After reaction was complete, the Raney Ni was
 25 filtered off (caution risk of fire) and the filtrate was concentrated to give

compound 2 (9.2 g, 46 mmol, 98% yield) as an oil which solidified under high vacuum drying. FAB MS $[M+1]^+$ 201.3.

To a solution of bromoacetyl derivative 3 (3.0 g, 6.2 mmol) (prepared in Example 3) in CH_2Cl_2 (62 mL) at -10°C were added Hünig's base (1.2 mL, 6.82 mmol) and compound 2 (2.48 g, 12.39 mmol). The solution was gradually warmed to RT overnight. After reaction was complete, CH_2Cl_2 (300 mL) was added and washed with brine (100 mL, 3x), dried over MgSO_4 and filtered. The filtrate was evaporated to dryness to give a light yellow solid which was purified by flash chromatography on flash grade silica gel (200 g), eluting with 5% $[\text{NH}_4\text{OH}/\text{MeOH} (1:9)] / \text{CH}_2\text{Cl}_2$ to give 71% yield of the title compound 4 as a white solid (2.66 g, 4.4 mmol), m.p. $78-81^\circ\text{C}$; FAB MS $[M+1]^+ + ^{35}\text{Cl}$ 603.1; Calcd. for $\text{C}_{31}\text{H}_{40}\text{N}_4\text{O}_4\text{Cl}_2$, C, 61.69; H, 6.68; N, 9.28; Cl, 11.74. Found: C, 61.33; H, 6.94; N, 9.17; Cl, 11.27.

15

EXAMPLE 8

Preparation of

(-)-1,1-dimethylethyl 4-[[2-[2-(3,4-dichlorophenyl)-1-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-1-piperidinecarboxylate (Enantiomer B)

20

By employing methods analogous to those described in Example 7 using chiral bromoacetyl compound (prepared in Example 5), the title compound was obtained as a white solid, m.p. $72-75^\circ\text{C}$; FAB MS $[M+1]^+ + ^{35}\text{Cl}$ 603.2;

$$[\alpha]_{\text{D}}^{22^\circ\text{C}} = -32.8^\circ (\text{MeOH}).$$


25

EXAMPLE 9

Preparation of

(+,-)-2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[(4-piperidinylamino)acetyl]piperazine, dihydrochloride

30



To a solution of (+,-)-1,1-dimethylethyl-4-[[2-[2-(3,4-dichlorophenyl)-1-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-1-piperidinecarboxylate (Example 7) (2.5 g, 4.14 mmol) in CH₂Cl₂ (20 mL) at 0 °C was added 4N HCl-dioxane (10.35 mL, 41.4 mmol). The mixture was stirred at 0 °C for 1 h and it was gradually warmed to RT over 3 h. After reaction was complete, excess HCl and solvent were evaporated to give a pale yellow solid which was used without further purification. FAB MS [M+1]⁺ ³⁵Cl 503.1

10

EXAMPLE 10

15


Preparation of

(-)-2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[(4-piperidinyl-amino)acetyl]piperazine, dihydrochloride (Enantiomer B)

By employing method analogous to that described in Example 9 using chiral material obtained from Example 8, the title compound was obtained

as a pale yellow solid, FAB MS [M+1]⁺ ³⁵Cl 503.2; $[\alpha]_D^{22.1^\circ} = -38^\circ$ (MeOH)

EXAMPLE 11



25


A series of Y derivatives of (-)-2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[(4-piperidinylamino)acetyl]piperazine, dihydrochloride (Enantiomer B) was prepared by parallel synthesis.

To a suspension of compound 1 obtained from Example 10 (1.05 g, 1.822 mmol) in CH₂Cl₂ (40 mL) was added Hünig's base (1.0 mL 5.74 mmol).


The mixture was dissolved by sonication. This solution was divided into 20 parts

- and transferred into 20 vials. Each vial contained 2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[(4-piperidinylamino)acetyl]piperazine, dihydrochloride (Enantiomer B) (0.091 mmol), Hünig's base (0.287 mmol) and CH₂Cl₂ (2 mL). To each vial was added separately 0.1 mmol of aromatic or substituted aromatic
- 5 methyl chloride or bromide or heterocyclic halide reagent. After reaction was complete it was diluted with CH₂Cl₂ (5 mL), washed with brine (2 mL 3x), dried (MgSO₄), filtered and evaporated to dryness.

Representative compounds 2 made by the above routes are shown below.



Y	FAB MS [M+1] ⁺ ³⁵ Cl	Y	FAB MS [M+1] ⁺ ³⁵ Cl
	638.2		594.2
	651.2		594.2
	650.2		612.2
	671.2		633.2
	618.1		601.1
	637.2		662.0
	636.2		651.1
	677.2		633.1
	673.9		663
	644.2		




Y	FAB MS [M+1] ⁺ ³⁵ Cl	Y	FAB MS [M+1] ⁺ ³⁵ Cl
	651.1		680.1
	693.1		641.1
	667.1		585.1
	688.1		679.1

EXAMPLE 12

Preparation of

- 5 (+,-)-1-benzoyl-4-[[2-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]piperidine



- 10 To a solution of compound obtained from Example 9 (0.23 g, 0.4 mmol) in CH₂Cl₂ (5 mL) was added Hünig's base (0.13 g, 1.0 mmol). This was followed by the addition of benzoic acid (49 mg, 0.4 mmol), HOBT (54 mg, 0.4 mmol), Et₃N (40 mg, 0.4 mmol) and DEC (77 mg, 0.4 mmol) at 0 °C. The


solution was gradually warmed to RT and stirred overnight. After reaction was complete, the solution was diluted with CH_2Cl_2 (50 mL) and washed with saturated NaHCO_3 solution (30 mL, 2x) and brine (20 mL, 3x). The organic layer was dried over MgSO_4 , filtered and concentrated to give crude material as an oil.

- 5 The product was purified by chromatography on flash grade silica gel (50 g), eluting with 5% $[\text{NH}_4\text{OH}/\text{MeOH} (1:9)]/\text{CH}_2\text{Cl}_2$ to give the title compound as a white solid (0.18 g), m.p. 94-96 °C; FAB MS $[\text{M}+1]^+ {}^{35}\text{Cl}$ 607.3.

EXAMPLE 13

Preparation of

- 10 (+,-)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-(2-oxo-2-phenylethyl)-4-piperidiny]amino]acetyl]piperazine




- 15 To a solution of compound 1 obtained from Example 9 (0.23 g, 0.4 mmol) in CH_2Cl_2 (5 mL) were added Hünig's base (0.21 g, 1.6 mmol) and phenylacetyl bromide (80 mg, 0.4 mmol) at RT. The mixture was stirred at RT overnight under N_2 . After reaction was complete, it was worked up and purified according to the methods described in Example 7 to give the title compound 2 as
- 20 a solid, m.p. 69-71 °C; FAB MS $[\text{M}+1]^+ {}^{35}\text{Cl}$ 621.3.

EXAMPLE 14

Preparation of

- 25 (+,-)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-(3-phenylpropyl)-4-piperidiny]amino]acetyl]piperazine




- To a solution of compound 1 obtained from Example 9 (0.4 g, 0.7 mmol) in $\text{CF}_3\text{CH}_2\text{OH}$ (5 mL) was added Hünig's base (0.21 g, 1.6 mmol) at 0 °C.
- 30 After stirring at 0 °C for 10 min, hydrocinnamaldehyde (94 mg, 0.7 mmol) was

added. The reaction was stirred at 0 °C for additional 2.5 h, and NaBH₃CN (100 mg, 1.6 mmol) was added. The mixture was stirred at 0 °C and gradually warmed to RT overnight. After reaction was complete, it was worked up and purified as described in Example 7 to give the title compound as a white solid, m.p. 52-54 °C; FAB MS [M+1]⁺ ³⁵Cl 621.3.

EXAMPLE 15

Preparation of

(-)-N-[4-[[4-[[2-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-1-piperidinyl]methyl]-2-thiazoyl]acetamide (Enantiomer B)




By an analogous method to that described in Example 13, using the chiral intermediate 1 made in Example 10 and 2-acetamido-4-(chloromethyl)-thiazole, in the presence of Hünig's base in CH₂Cl₂, the title compound 2 was obtained as a white solid after purification by flash grade silica gel chromatography, m.p. 104-107 °C, HRMS Calcd. for [M+H]⁺ (2x³⁵Cl)

C₃₂H₃₉N₆SO₃Cl₂ 657.2181; Found 657.2172; $[\alpha]_D^{24.1} = -40.1^{\circ}$ (MeOH).

EXAMPLE 16

Preparation of

(+,-)-2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[[[3-methyl-1-(phenylmethyl)-4-piperidinyl]amino]acetyl]piperazine (diastereomers A and B)



Step 1

To a solution of BOC glycine (0.979 g, 5.59 mmol) and Et₃N (0.85 mL, 6.1 mmol) in CH₂Cl₂ (10 mL) was added BOP (benzotriazol-1-yloxy-
 5 tris(dimethylamino)phosphonium hexafluorophosphate) reagent (2.46 g, 5.57 mmol). After stirring for 15 min, (+,-)-(3,5-dimethylbenzoyl)-3-(3,4-dichlorophenyl)piperazine (1.83 g, 5.03 mmol) (prepared in Example 2) was added. After 5 h, the reaction mixture was added to 0.2 N HCl (100 mL) and extracted with CH₂Cl₂ (3 x 60 mL). The combined organic layers were washed
 10 with brine, dried with MgSO₄ and concentrated. The crude material was purified by flash chromatography on silica gel eluting with 50:1 to 30:1 CH₂Cl₂-MeOH to give 2.15 g of compound 2 (shown above) as a white foam (4.1 mmol, 82%).

Step 2

Compound 2 (1.32 g, 2.5 mmol) was treated with MeOH saturated
 15 HCl (15 mL) for 2.5 h and concentrated. The resulting powder was dissolved in CH₂Cl₂, washed with sat. NaHCO₃, dried with MgSO₄ and concentrated to give compound 3 as the free base.

Step 3

To a -78°C solution of LDA (10.79 mmol) in THF (30 mL) was
 20 added 1-benzyl-4-piperidone (2.0 mL, 10.8 mmol). The reaction mixture was warmed to 0°C for 20 min and then cooled back to -78°C. Methyl iodide (0.67 mL, 10.8 mmol) was added to the enolate solution which was stirred at 0°C for

2 h then warmed to RT overnight. The reaction mixture was quenched with sat. NH_4Cl and concentrated. The residue was suspended in H_2O and extracted with CH_2Cl_2 . The combined organic layers were dried with MgSO_4 , filtered and concentrated. The product was purified by flash chromatography on silica gel eluting with 1:1 hexane-EtOAc to give the 1-benzyl-3-methyl-4-piperidone **4** as a yellow oil (0.65 g, 30%).

Step 4

A mixture of the ketone **4** from step 3 (70 mg, 0.13 mmol) and the compound **3** (34 mg, 0.17 mmol) was stirred in titanium isopropoxide (45 mg, 0.16 mmol) for 1.5 h. To the mixture were added ethanol (1.0 mL) and NaCNBH_3 (5.4 mg, 8.6 mmol) and the mixture was stirred overnight. The reaction mixture was filtered and washed with EtOAc. The filtrate was washed with H_2O and brine, dried with MgSO_4 and concentrated. The residue was chromatographed on silica gel eluting with 5% NH_3 sat. MeOH in CH_2Cl_2 to give both diastereomers pure.


Diastereomer A (15 mg) HRMS (FAB, $\text{M}+\text{H}^+$): m/e calc'd for $[\text{C}_{34}\text{H}_{41}\text{N}_4\text{Cl}_2\text{O}_2]^+$ 607.2607; found 607.2603.

Diastereomer B (17 mg) HRMS (FAB, $\text{M}+\text{H}^+$): m/e calc'd for $[\text{C}_{34}\text{H}_{41}\text{N}_4\text{Cl}_2\text{O}_2]^+$ 607.2607; found 607.2597.

EXAMPLE 17

Preparation of

2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[[[1-(phenylmethyl)-3-piperidinyl]amino]acetyl]piperazine, diastereomers



By a procedure analogous to the method described in Example 16 step 4, using 3-benzyl piperidine in place of 1-benzyl-3-methyl-4-piperidone, the title compound was prepared as a solid foam.


HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{33}H_{39}N_4Cl_2O_2]^+$ 593.2450; found 593.2458.

EXAMPLE 18

Preparation of

5

2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]piperazine




By an analogous method to that described in Example 16, the product from Example 16, compound 3 (185 mg, 0.44 mmol) was combined with 8-benzyl-8-azabicyclo[3.2.1]octan-3-one (97 mg, 0.45 mmol) and $Ti(O-iPr)_4$ (105 mL, 0.50 mmol) and left stirring for 1 h. To the thick reaction mixture was added $NaBH_3CN$ (59.5 mg, 0.95 mmol) and the mixture was stirred overnight. To the reaction mixture was added H_2O (1 mL) and it was filtered. The filtrate was washed with EtOH, concentrated and purified by silica gel chromatography, eluting with 30:1:0.1 to 15:1:0.1 CH_2Cl_2 -MeOH- NH_3 aq. to give the title product as a white foam. HRMS (FAB, $M+H^+$): m/e calc'd $[C_{35}H_{41}Cl_2N_4O_2]^+$: 619.2607, found 619.2594.

20

EXAMPLE 19

Preparation of

2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]piperazine (enantiomer B)




This compound was prepared by a procedure analogous to Example 16 except for the use of (+)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)-piperazine (Enantiomer B) in step1 and tropinone in place of 1-benzyl-3-methyl-4-piperidone. HRMS (FAB, M+H⁺); m/e calc'd [C₂₉H₃₇Cl₂N₄O₂]⁺:
5 543.2294, found 543.2282.

EXAMPLE 20

Preparation of

2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[[[1,3-bis(phenylmethyl)-4-
10 piperidiny]amino]acetyl]piperazine, diastereomers from enantiomer B



Step 1. A solution of 1-benzyl-3-carbomethoxy-4-piperidone (1.0 g, 4.0 mmol) in THF (10 mL) was treated with 0.5 M potassium bis(trimethylsilyl)amide in toluene (9.6 mL, 4.8 mmol) for 15 min, followed by
15 the addition of benzyl bromide (1.2 g, 4.8 mmol). After 2 h, the reaction mixture was quenched with sat. NH₄Cl and extracted with ether. The combined organic layers were washed with brine, dried with MgSO₄ and concentrated. The product was purified by silica gel chromatography eluting with 4:1 hexane-EtOAc to give 3-carbomethoxy-1,3-dibenzyl-4-piperidone
20 (0.61 g) as a light yellow oil.

Step 2. A solution of 3-carbomethoxy-1,3-dibenzyl-4-piperidone (0.61 g, 1.78 mmol), MeOH (10 mL) and 5 M HCl aq. (25 mL, 125 mmol) was refluxed overnight. The reaction mixture was concentrated and
25 chromatographed (silica gel, eluting with 4:1 hexane-EtOAc) to give 1,3-dibenzyl-4-piperidone (0.31 g).

Step 3. A solution of 1,3-dibenzyl-4-piperidone (0.033 g, 0.12 mmol) and [[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-amino]acetyl]-piperazine
30 (Enantiomer B) (0.05g, 0.12 mmol) [prepared according to the methods

described in Example 16, except using (+)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (Enantiomer B) (Example 4) in step 1] in CH₂Cl₂ (1.0 mL) was treated with NaBH(OAc)₃ (0.035 g, 0.16 mmol) and acetic acid (0.07 mL, 0.12 mmol). The mixture was stirred overnight. After completion, the reaction mixture was quenched with 1N NaOH and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried with MgSO₄, concentrated and purified by silica gel chromatography, eluting with 5% NH₃ sat. MeOH/CH₂Cl₂ to give 32 mg of the titled product as a white solid. HRMS (FAB, M+H⁺); m/e calc'd [C₄₀H₄₅Cl₂N₄O₂]⁺: 683.2920, found 683.2932.

EXAMPLE 21

Preparation of


2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[[[3-methyl-1-(phenylmethyl)-4-piperidiny]amino]acetyl]piperazine (diastereomers A from enantiomer B)

This compound was prepared by a procedure analogous to Example 16 except for the using of (+)-[3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)-piperazine (Enantiomer B) in Example 16, step 1. HRMS (FAB, M+H⁺); m/e calc'd [C₃₄H₄₁Cl₂N₄O₂]⁺: 607.2607, found 607.2594.

EXAMPLE 22

Preparation of

2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[[[1-(phenylmethyl)-3-(2-propenyl)-4-piperidiny]amino]acetyl]piperazine (diastereomers from enantiomer B)




This compound was prepared by a procedure analogous to Example 20 except for the substitution of allyl bromide in place of benzyl bromide in step

1. HRMS (FAB, M+H⁺); m/e calc'd [C₃₆H₄₃Cl₂N₄O₂]⁺: 633.27, found 633.2763.

EXAMPLE 23

Preparation of

trichloroethyl-4-[[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-2-phenyl-1-piperidinecarboxylate (diastereomers from enantiomer B)



- 10 Step 1. To a cooled solution of THF (100 mL) containing 4-methoxypyridine (3.5 g, 32.5 mmol) (prepared according to *Synthesis* 1989, 645, at -15°C was added 2,2,2-trichloroethyl chloroformate (4.5 mL, 32.7 mmol). After 30 min. at -15°C, 2M PhMgCl in THF (19.5 mL, 39 mmol) was added and the mixture was stirred at -15°C for 30 min. followed by 30 min.
- 15 at RT. The reaction mixture was quenched with 10% aq. HCl (100 mL), added to brine (200 mL) and partitioned. The aqueous layer was extracted with Et₂O (50 mL). The combined organic layers were dried with MgSO₄ and concentrated to give 11.4 g of compound 3 shown above as a light tan solid.
- 20 Step 2. To a cooled solution of compound 3 from step 1 (8.65 g, 34.8 mmol) in THF (100 mL) at -23°C was added 27.8mL of 1M L-selectride (27.8 mmol). The mixture was stirred at -23°C for 2 h. After warming to RT, the


reaction mixture was added to sat. NaHCO_3 and partitioned. The aqueous layer was extracted with Et_2O (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried with MgSO_4 and concentrated. The product was purified by silica gel chromatography eluting with 6:1 to 3:1
 5 hexane-EtOAc to give 2.47 g of compound 4 and 2.75 g of recovered starting material.

Step 3. To a solution containing the compound 4 from step 2 (284 mg, 0.81 mmol) in 1,2-dichloroethane (3 mL) and compound 5 (324 mg, 0.81 mmol) [made in Example 16, step 3 except using (+)-[3,5-dimethylbenzoyl]-
 10 3-(3,4-dichlorophenyl)piperazine (Enantiomer B) in step 1] was added $\text{NaBH}(\text{OAc})_3$ (179 mg, 0.84 mmol) and acetic acid (50 mL, 0.87 mmol). After stirring overnight, the reaction mixture was added to 1N NaOH (40 mL) and was extracted with Et_2O (3 x 15 mL). The combined organic layers were washed with brine (15 mL), concentrated, and purified by silica gel
 15 chromatography eluting with 25:1:0.1 CH_2Cl_2 -MeOH- NH_3 aq to give 423 mg of the title compound as a white foam. HRMS (FAB, $\text{M}+\text{H}^+$); m/e calc'd $[\text{C}_{35}\text{H}_{38}\text{Cl}_4\text{N}_4\text{O}_4]^+$: 753.1336, found 753.1338.

EXAMPLE 24

Preparation of

20 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[3-[5-(phenylmethyl)-(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-yl]-1-oxopropyl]piperazine (diastereomer A from enantiomer B)





25 To a cooled solution of CH_2Cl_2 (10 mL) containing diisopropylethylamine (0.275 mL, 2.0 mmol) and [3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (Enantiomer B) (Example 4) (305 mg, 0.84 mmol) was added chloropropionyl chloride (0.075 mL, 0.8 mmol). The reaction mixture was allowed to warm to room temperature. After 20
 30 minutes, (1S,4S)-2-benzyl-2,5-diazabicyclo(2.2.1)heptane-2HBr (297 mg, 0.85 mmol) and diisopropylethylamine (0.275 mL, 2.0 mmol) were added

and the mixture was left over night, after which the reaction mixture was concentrated. The product was purified by flash chromatography on flash grade silica gel, eluting with 30:1:0.1 CH₂Cl₂/MeOH/NH₃ to give a foamy solid (140 mg, 0.23 mmol, 29%), High Res. MS:[M+1]⁺ calcd. for C₃₄H₃₉Cl₂N₄O₂ 605.2450; Found, 605.2465.

EXAMPLE 25


Preparation of



10 A series of urea analogs of (-)-2-(3,4-dichlorophenyl)-4-[3,5-dimethylbenzoyl]-1-[(4-piperidinyl-amino)acetyl]piperazine, dihydrochloride (Enantiomer B) (Example 10) as shown above was prepared by parallel synthesis. The product from Example 10 (0.75 g, 1.3 mmol) was dissolved in dry pyridine (13 mL). 1 ml of the above solution was transferred into a vial (2


15 dram size). To each vial was added 0.1 mmol of an aromatic or substituted aromatic isocyanate reagent. After completion the reaction was diluted with CH₂Cl₂ (5 mL) and washed with water (3x5 mL), dried over Na₂SO₄, filtered and evaporated to dryness. Most of reactive reagents gave (2:1) adduct B as the major product. Several less reactive reagents gave the product A. Crude

20 products were identified by FAB MS.



y = aromatic or substituted
aromatic group or cycloalkyl


and




y = aromatic or substituted
aromatic group or cycloalkyl

Y	Product	FAB MS [M+1] ⁺ ³⁵ Cl	Y	Product	FAB MS [M+1] ⁺ ³⁵ Cl
	B	741.1		A	694.4
	B	833.3		A	692.2
	B	797		B	769.3
	B	909		A	647.3
	A	664.3		B	797.4
	B	841.4		B	753.5
	A	672.3			
	B	801			

EXAMPLE 26



- A series of amido analogs of (-)-2-(3,4-dichlorophenyl)-4-[3,5-
 5 dimethylbenzoyl-1-[(4-piperidinyl-amino)acetyl]piperazine, dihydrochloride
 (Enantiomer B) (Example 10) shown above were prepared by parallel synthesis.
 The chiral product from Example 10 (1.15 g, 2 mmol) was dissolved in a mixture
 of dry CH₂Cl₂ (20 mL) and Hünig's base (0.9 g, 7 mmol) followed by the addition
 of HOBT (0.3 g, 2.2 mmol). After stirring at RT for one hour, 1 mL of this
 10 solution was transferred into a brown vial (4 dram size). To each vial was added
 the appropriate aromatic or heterocyclic acid (0.1 mmol). DEC (0.38 g, 2 mmol)
 was dissolved in CH₂Cl₂ (5 mL) and Et₃N (0.2 mL) and 0.4 mL (0.2 mmol) of this
 DEC solution was added into each vial. The reaction was stirred at RT
 overnight. After completion each reaction mixture was diluted with CH₂Cl₂ (4
 15 mL) and washed with water (2 x 4 mL), dried over Na₂SO₄, filtered and
 evaporated to dryness. Crude product was identified by FAB MS.




Y	FAB MS [M+1] ⁺ ³⁵ Cl	Y	FAB MS [M+1] ⁺ ³⁵ Cl
	607.5		597.7
	624.4		607.8
	660.2		612.7
	597.6		608.8
	663.1		674.7
	609.5		614.8
	597.6		698.7
	676.3		682.7
	658.2		677.7
	613.5		607.8

EXAMPLE 27

Preparation of

- 5 (-)-phenyl 4-[[2-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-1-piperidinecarboxylate, hemihydrate (Enantiomer B)




- 10 To a cold solution of compound 1 from Example 10 (0.2 g, 0.347 mmol) in CH_2Cl_2 (8 mL) at -78°C was added Hünig's base (0.193 mL, 1.11 mmol) and phenylchloroformate (0.046 mL, 0.364 mmol). After stirring at -78°C for 24 h, the reaction was diluted with CH_2Cl_2 (200 mL), washed with brine (80 mL, 3x), dried (MgSO_4), filtered and evaporated to dryness. The crude material was purified by flash chromatography, using flash grade silica gel (50 g), eluting with 5% [(1:9) (NH_4OH / MeOH)] / 95% CH_2Cl_2 to give a 50% yield of the title compound 2 as a
- 15 white solid (0.108 g, 0.173 mmol), m.p. $71-75^\circ\text{C}$; FAB MS $[\text{M}+1]^+$ ^{35}Cl 623.0; Calcd. for $\text{C}_{33}\text{H}_{36}\text{N}_4\text{O}_4\text{Cl}_2 \cdot 0.5 \text{H}_2\text{O}$, C, 62.66; H, 5.90; N, 8.86; Cl 11.38.

Found: C, 62.52; H, 5.95; N, 8.87; Cl, 11.01; $[\alpha]_D^{24.2^\circ} = -42.0^\circ$ (MeOH).

EXAMPLE 28

Preparation of


- 20 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-[(1H-pyrrol-2-yl)methyl]-4-piperidiny]amino]acetyl]piperazine, hemihydrate (Enantiomer B)



To a solution of compound 1 from Example 10 (0.2 g, 0.347 mmol) in $\text{CF}_3\text{CH}_2\text{OH}$ (3.47 mL) was added Hünig's base (0.12 mL, 0.694 mmol) and pyrrole-2-carboxaldehyde (40 mg, 0.42 mmol) at RT under nitrogen. After stirring at RT for 1 h, NaBH_3CN (67 mg, 0.694 mmol) was added and the mixture was stirred overnight. After the reaction was complete, solvent was evaporated and the residue was mixed with 5% NaHCO_3 solution (50 mL) and brine (100 mL) then it was extracted with CH_2Cl_2 (80 mL, 3x). The organic layers were combined, dried (MgSO_4), filtered and evaporated to dryness. The crude material was purified by flash chromatography on flash grade silica gel (50 g), eluting with 7.5% [(1:9)(NH_4OH / MeOH)] / 92.5% CH_2Cl_2 to give the title compound 2 in 43% of yield as a white solid, m.p. 73-76 °C; HRMS, Calcd. for $[\text{M}+\text{H}]^+$ ^{35}Cl $\text{C}_{31}\text{H}_{38}\text{N}_5\text{O}_2\text{Cl}_2$: 582.2403 Found: 582.2403.

EXAMPLE 29

Preparation of
2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-[(1H-pyrrol-2-yl)carbonyl]-4-piperidiny]amino]acetyl]piperazine, hemihydrate (Enantiomer B)



By an analogous method to that described in Example 26, using the chiral compound 1 from Example 10 (100 mg, 0.173 mmol) and pyrrole-2-carboxylic

acid (20 mg, 0.178 mmol), the title compound 2 was obtained as a white solid after flash grade silica gel chromatography, m.p. 95-100 °C; HRMS, Calcd. for $[M+H]^+$ ^{35}Cl , $\text{C}_{31}\text{H}_{36}\text{N}_5\text{O}_3\text{Cl}_2$: 596.2159 Found: 596.2204.


5

EXAMPLE 30

10

Preparation of

(-)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[[[1-[(1H-imidazol-2-yl)methyl]-4-piperidiny]amino]acetyl]piperazine, dihydrate (Enantiomer B)



15

By an analogous method to that described in Example 28, using the chiral compound 1 from Example 10, (200 mg, 0.347 mmol) and 2-imidazole-carboxaldehyde (34 mg, 0.347 mmol), the title compound 2 was obtained as a white solid after flash grade silica gel chromatography, m.p. 73-76 °C; HRMS, Calcd. for $[M+H]^+$ ^{35}Cl , $\text{C}_{30}\text{H}_{37}\text{N}_6\text{O}_2\text{Cl}_2$: 583.2355 Found: 583.2369;

20


$$[\alpha]_D^{23.7^\circ} = -46.5^\circ (\text{MeOH})$$

Example 31

25

Preparation of

2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[1-oxo-3-[[1-(phenylmethyl)-4-piperidiny]amino]propyl]piperazine (Enantiomer B)




- Step 1. To a cold solution of [3,5-dimethylbenzoyl]-3-(3,4-dichlorophenyl)piperazine (Enantiomer B) **1** (3.0 g, 8.26 mmol) (Example 4) in CH₂Cl₂ (82.6 mL) at -78 °C was added Hünig's base (1.582 mL, 9.08 mmol) and bromopropionyl chloride (0.874 mL, 8.67 mmol). After stirring at -78 °C for 5 h, the reaction mixture was diluted with CH₂Cl₂ (300 mL), washed with brine (150 mL, 2x), dried with MgSO₄, filtered and concentrated to dryness to give the crude bromopropionyl intermediate **2** (3.2 g).
- Step 2. To a solution of compound **2** (300 mg, 0.6 mmol) in CH₂Cl₂ (6 mL) were added 4-amino-1-benzyl piperidine (0.245 mL, 1.2 mmol) and Hünig's base (0.1 mL, 0.6 mmol) at 0 °C. The reaction was gradually warmed to RT and stirred for 3 days. After completion the reaction mixture was diluted with CH₂Cl₂ (200 mL) and washed with brine (50 mL, 2x), dried over MgSO₄, filtered and concentrated to dryness to give a light yellow solid. The crude material was purified by flash chromatography on flash grade silica gel (80 g), eluting with 6.5% [(1:9) (NH₄OH / MeOH)] / 93.5% CH₂Cl₂ to give the title compound as a white solid (0.18 g, 0.3 mmol, 50%), m.p. 51-54 °C; HRMS, Calcd. for [M+H]⁺ ³⁵ Cl, C₃₄H₄₁N₄O₂Cl₂ : 607.2607 Found: 607.2600.

EXAMPLE 32

Preparation of

2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[1-oxo-3-N-methyl-[[1-(phenylmethyl)-4-piperidiny]amino]propyl]piperazine (Enantiomer B)




4-Methylamino-1-benzyl piperidine 3 was prepared analogous to the reductive amination method described in Example 28 using 4-amino-1-benzyl piperidine and methylamino hydrochloride as starting materials.

The title compound 4 was prepared as a white solid, analogous to the methods described in Example 31, except using 4-methylamino-1-benzyl piperidine 3 in place of 4-amino-1-benzyl piperidine in step 2. m.p. 47-49 °C; FAB MS $[M+1]^+$ ^{35}Cl 621.2; Calcd. for $\text{C}_{35}\text{H}_{42}\text{N}_4\text{O}_2\text{Cl}_2 \cdot 0.5 \text{H}_2\text{O}$: C, 66.66; H, 6.87; N, 8.88; Cl, 11.24. Found: C, 67.02; H, 7.07; N, 8.81; Cl, 10.75.

EXAMPLE 33

Preparation of

(-)-1,2-dimethylethyl 5-[3-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-3-oxopropyl]-(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (diastereomer A from enantiomer B)



The title compound 4 was prepared as a white solid analogous to the methods described in Example 31 except using (1s,4s)-N-t-BOC-2,5-diazobicyclo[2.2.1]-heptane in place of 4-amino-1-benzyl piperidine in step

2. m.p. 78-82 °C; FAB MS $[M+1]^+$ + 35 Cl 615.1; $[\alpha]_D^{22.0} = -51.1^\circ$ (MeOH).


Example 34

10

Preparation of

(-)-1-[3-(1S,4S)-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-1-oxopropyl]-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl) piperazine dihydrochloride (diastereomer A from enantiomer B)

15




- 5 To a solution of compound 1 obtained from Example 33 (0.74g, 1.2 mmol) in CH_2Cl_2 (6 mL) at RT was added 4N HCl (3mL, 12 mmol). After stirring at RT for 4 h, excess acid and solvents were evaporated to give a light yellow solid 2, m.p. 60-64 °C; FAB MS $[\text{M}+1]^+$ 35Cl 515.1; $[\alpha]_{\text{D}}^{22.0^\circ} = -34.4^\circ$ (MeOH).

10

Example 35

Preparation of

- 15 (-)-N-[4-[[5-[3-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-3-oxopropyl]-(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl-2-thiazoly]]acetamide (diastereomer A from enantiomer B)




- By an analogous method to that described in Example 13, using the chiral intermediate 1 made in Example 34 and 2-acetamido-4-chloromethyl thiazole, in the present of Hünig's base in CH₂Cl₂, the title compound 2 was obtained as a white solid 2 after purification by flash grade silica gel chromatography, m.p. 105-110 °C; FAB MS [M+1]⁺ ³⁵Cl 669.0; $[\alpha]_D^{24.7^\circ} = -23.4^\circ$ (MeOH).

10

EXAMPLE 36

Preparation of

- (-)-N-[4-[[5-[3-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-3-oxopropyl]-(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]acetamide (diastereomer A from enantiomer B)




By an analogous method to that described in Example 13, using the chiral intermediate made in Example 34 and 4-acetamidobenzyl chloride, in the presence of Hünig's base in CH_2Cl_2 , the title compound 2 was obtained as a white solid after purification by flash grade silica gel chromatography, m.p. 101-106 °C; FAB MS $[\text{M}+1]^+ {}^{35}\text{Cl}$ 662.1; $[\alpha]_{\text{D}}^{23.3^\circ} = -27.3^\circ (\text{MeOH})$.

10

EXAMPLE 37

Preparation of
 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[3-[5-(1H-pyrrol-2-yl)methyl]-(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1-oxopropyl] piperazine (diastereomer A from enantiomer B)

15




By an analogous method to that described in Example 28, using the chiral intermediate of Example 34, the title compound 2 was obtained as a white solid after purification by flash grade silica gel chromatography, m.p.

5 81-83 °C; FAB MS [M+1]⁺ ³⁵Cl 594.1

EXAMPLE 38

Preparation of

10 (+,-)-2-(3,4-dichlorophenyl)-4-[(4-fluoro-1-naphthalenyl)carbonyl]-1-[[[1-(phenylmethyl)-4-piperidiny]amino]acetyl]piperazine



General Method

To a cooled solution of (+,-)-2-(3,4-dichlorophenyl)piperazine (1; $\text{Ar}^2 = 3,4\text{-dichlorophenyl}$) (20g, 86.53 mmol) in MeOH (900 mL) at -78°C was added dropwise a solution of t-BOC anhydride (19.47g, 86.53 mmol) in MeOH (263 mL) over 3h period under N_2 . The solution was gradually warmed up to RT overnight. After reaction was complete, the solvent was evaporated and the residue was dried under high vacuum overnight to give 2 (28 g) as a white solid. ($\text{Ar}^2 = 3,4\text{-dichlorophenyl}$) FAB Mass $[\text{M}+1]^+$ ^{35}Cl 331.2.

To a cooled solution of compound 2 (23.8g, 71.85 mmol) in CH_2Cl_2 (500 mL) at -78°C was added a solution of bromoacetyl bromide (6.88 mL, 79.04 mmol) in CH_2Cl_2 (10 mL) through a dropping funnel under N_2 over a 10 min. period. After stirring at -78°C for 3 h, TLC showed that the reaction was complete. To this cooled solution were added Hunig's base (13.76 mL, 79 mmol) and 4-amino-1-benzylpiperidine (29.30 mL, 143.7 mmol). It was kept at -78°C for one hour then gradually warmed up to RT overnight. After completion CH_2Cl_2 (200 mL) was added and washed with brine (200 mL, 3x), dried over MgSO_4 , filtered and concentrated to give a light brown residue of compound 3 (46g) ($\text{Ar}^2 = 3,4\text{-dichlorophenyl}$).





dichlorophenyl). Compound 3 was purified by flash chromatography on 400g of flash grade silica gel, eluting with 3.5 % NH₃-MeOH/CH₂Cl₂ to give 24.8 g (44.2 mmol, 61.5 %) of pure compound 3 (Ar² = 3,4-dichlorophenyl). FAB MS [M+1]⁺ ³⁵Cl 561.3

5 To a solution of compound 3 (Ar² = 3,4-dichlorophenyl) (16g, 28.49 mmol) in CH₂Cl₂ (142.5 mL) at 0 °C was added 4N HCl-dioxane solution (71.24 mL, 284.9 mmol) through a dropping funnel. The reaction was gradually warmed up to RT and stirred for 4h. After completion the solvents were evaporated to give a light yellow solid which was dissolved in
10 H₂O (400 mL) and brought to pH 10 with 1 N NaOH. The product was extracted from basic aqueous solution with CH₂Cl₂(200mL, 4x), dried over MgSO₄, filtered and concentrated to give compound 4 (Ar² = 3,4-dichlorophenyl) as a light yellow solid (12.5g, 27.09 mmol, 95%). FAB MS [M+1]⁺³⁵ Cl 461.1 Compound 4 was the key intermediate which was used
15 to couple with various aromatic acid for the synthesis of many compounds.

 To a solution of compound 4 (Ar² = 3,4-dichlorophenyl) (200 mg, 0.433 mmol) in CH₂Cl₂ (5 mL) were sequentially added 4-fluoro-1-naphthoic acid (84.8 mg, 0.433 mmol), HOBT (58.5 mg, 0.434 mmol), Et₃N (0.634 mL, 0.455 mmol) and DEC (85 mg, 0.434 mmol) at RT. The reaction
20 was stirred at RT under N₂ overnight. After completion the reaction was diluted with EtOAc (150 mL) and washed with brine (50 mL, 3x), dried over MgSO₄, filtered and concentrated to give a crude product 5 (Ar² = 3,4-dichlorophenyl, Ar¹ = 4-fluoro-1-naphthyl) which was purified by flash chromatography (50 g flash grade silica gel), eluting with 4% sat'd NH₃-
25 MeOH in CH₂Cl₂ to give pure compound 5 Fab Mass [M+1]⁺ ³⁵Cl 633.2, m.p. 78-81 °C.

EXAMPLE 39

30 The following compounds were prepared according to the procedures described in Example 38. The key intermediate compound 4 (Ar² = 3,4-dichlorophenyl) was coupled with the appropriate aromatic acid to obtain the target compounds. Those compounds without melting points were prepared via parallel synthesis.


	FAB and / or CI MS [M+1] ⁺ ³⁵ Cl	M.P. °C
	634 / 636 (M+1) ⁺ for (4x ³⁵ Cl)/(3x ³⁵ Cl+1x ³⁷ Cl)	
	655.1	70-73
	658	Calcd. for C ₃₇ H ₄₁ N ₅ O ₂ Cl ₂ • 3 HCl • 3 H ₂ O C, 54.06; H, 6.13; N, 8.52 Found: C, 54.28; H, 6.23; N, 8.77
made pure from chiral enantiomer B intermediate 4 analogous to Example 38		
	614	Calcd. for C ₃₀ H ₃₁ N ₅ O ₂ Cl ₄ • 2 HCl • 2 H ₂ O C, 48.41; H, 5.01; N, 9.41 Found: C, 48.16; H, 5.41; N, 9.30
made pure from chiral enantiomer B intermediate 4 analogous to Example 38		

5

10

WHAT IS CLAIMED IS:

1. A compound of the formula:




5

each X is independently, O, (H,H), NR_d, or S;

n is 0 to 2; u is 0 to 2; l is 0 to 2;

m is 1, and y is 1 to 3; or m is 2, and y is 0;

and with the further proviso that no more than one R_c is other than H in the




10

moiety;

each R_c is independently H, C₁-C₆ alkyl, -(CH₂)_{n₁}-R₄ where n₁ is 1 to 6;

R_d is independently selected from the group consisting of H, C₁-C₆ alkyl, CN, OR_a, phenyl, substituted phenyl, benzyl, substituted benzyl, or allyl;

15



5

R_C ' is H, C_1 - C_6 alkyl or $(CH_2)_nOR_a$, with the proviso that no more than one R_C is other than H;


each R_a and R_b is independently selected from the group consisting of H, C_1 - C_6 alkyl, phenyl, substituted phenyl, benzyl, substituted benzyl,

- 10 allyl; with the proviso that when R_4 is $-N(R_b)C(=O)OR_a$, R_a is not H; or when R_a and R_b are attached to the same nitrogen, then R_a and R_b together with the nitrogen to which they are attached, form a 4 to 7 member ring;

wherein each R_1 and R_2 is independently H, C_1 - C_6 alkyl, CF_3 ,

- C_2F_5 , Cl, Br, I, F, NO_2 , OR_a , CN, NR_aR_b , $-C(=O)Ra$, $-O-C(=O)Ra$,
 15 $-O-C(=O)N(R_a)(R_b)-$, $-N(R_b)C(=O)OR_a$, $-N(R_a)C(=O)R_b$, $-C(=O)OR_a$, $-C(=O)N(R_a)(R_b)-$,
 $-S(=O)-Ra$, $-S(=O)(=O)Ra$, $-SR_a$, and $-S(=O)(=O)NHR_a$; and where R_a is not H
 in $-S(=O)-Ra$, $-S(=O)(=O)Ra$, or $-N(R_b)C(=O)OR_a$;

or when R_1 and R_2 are on adjacent carbons on a ring, they can form




wherein n' is 1 or 2;

and each R_3 is independently H, C_1 - C_6 alkyl, CF_3 , C_2F_5 , $\text{---}\overset{\text{O}}{\parallel}\text{C---Ra}$,

5 $\text{---}\overset{\text{O}}{\parallel}\text{C---Ra}$, $\text{---}\overset{\text{O}}{\parallel}\text{C---N(R}_a\text{)(R}_b\text{)}$ Cl, Br, I, F, OR_a , OCF_3 , or phenyl;

Ar_1 is heteroaryl or substituted heteroaryl,




10

or



Q is N or CH;

Ar_2 is heteroaryl or substituted heteroaryl;




15

Z is



5



$m_1 = 0-1$; $m_2 = 1-2$; n_3 is $0-4$;


- 10 R_9 is $-OR_a$ with the proviso that R_a is not H; aryl, substituted aryl, heteroaryl, substituted heteroaryl, $-NR_aR_b$, $-O-(CR_a,R_b)^{n_7}$ -aryl, $-O-(CR_a,R_b)^{n_7}$ -substituted aryl, $-O-(CR_a,R_b)^{n_7}$ -heteroaryl, $-O-(CR_a,R_b)^{n_7}$ -substituted heteroaryl, $-NR_a-(CR_a,R_b)^{n_7}$ -heteroaryl, $-NR_a-(CR_a,R_b)^{n_7}$ -substituted heteroaryl, $-O-(CR_a,R_b)^{n_7}$ -heterocycloalkyl, $-O-(CR_a,R_b)^{n_7}$ -substituted heterocycloalkyl, $-NR_a-(CR_a,R_b)^{n_7}$ -aryl, $-NR_a-(CR_a,R_b)^{n_7}$ -
- 15

substituted aryl, $-NR_a-(CR_a,R_b)n_7$ -heterocycloalkyl, $-NR_a-(CR_a,R_b)n_7$ -substituted heterocycloalkyl;

n_7 is 0 to 4;

each R_e and R_f is independently selected from the group consisting of H,

- 5 C_1 - C_6 alkyl, phenyl, substituted phenyl, benzyl, substituted benzyl, allyl; or R_e and R_f taken together with the carbon to which they are attached can also form a carbonyl group with the proviso that no more than one carbonyl



group is in the

moiety;




n_5 is 1 to 2;

- 10 each R_5 is independently selected from the group consisting of H, OH,


$\text{---}\overset{\text{O}}{\parallel}\text{C---}R_a$, C_1 - C_6 alkyl, $(CH_2)_{n_1}\text{---}R_4$, wherein n_1 is 1 to 6 with the proviso that when n_1 is 1, R_4 is not OH or NR_aR_b ; also with the proviso that when n_5 is 2, R_5 is C_1 - C_6 alkyl and two R_5 can be attached to the nitrogen to form a quaternary salt:

15

R_6 is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl,



or





- wherein X_3 is (H,H), O, NR_d , or S,
 or R_6 is heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted
 heterocycloalkyl when n_3 is 0-4;
- 5 when R_e, R_f taken together with the carbon atom to which they are attached
 form a carbonyl group and n_3 is 1, R_6 can also be $-OR_a$ wherein R_a is not H,
 or R_6 is $-NR_a, R_b$, $-O-(CR_a, R_b)_{n_7}$ -heteroaryl, $-O-(CR_a, R_b)_{n_7}$ -substituted
 heteroaryl, $-O-(CR_a, R_b)_{n_7}$ -heterocycloalkyl, $-O-(CR_a, R_b)_{n_7}$ -substituted
 heterocycloalkyl, $-O-(CR_a, R_b)_{n_7}$ -aryl, $-O-(CR_a, R_b)_{n_7}$ -substituted aryl,
 10 $-NR_a-(CR_a, R_b)_{n_7}$ -heteroaryl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted heteroaryl,
 $-NR_a-(CR_a, R_b)_{n_7}$ -aryl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted aryl, $-NR_a-(CR_a, R_b)_{n_7}$ -
 heterocycloalkyl, $-NR_a-(CR_a, R_b)_{n_7}$ -substituted heterocycloalkyl, wherein R_a
 and R_b are each independently selected from the group consisting of H
 and C_1 - C_6 alkyl;
- 15 or any enantiomer thereof,
 or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein m is 1; both X's are
 O; l is 0; n is 1; u is 0; and y is 1 to 3;

20

and Ar_1 is







wherein Q is N or CH;

- 5 each X_1 is independently O, S or NR_a ;
 each X_2 is independently CH or N; and
 n_4 is 0 or 1;


and wherein Ar_2 is



3. A compound according to claim 2 wherein Z is




4. A compound according to claim 2 wherein Z is




5

5. A compound according to claim 2 wherein Z is




10


6. A compound according to claim 2 wherein R_E , or R_f is H or C_1 - C_6 alkyl or allyl, n_3 is 0-4, n_7 is 0 to 4; and R_6 is




10 or wherein R_E , R_f taken together with the carbon to which they are attached form a carbonyl group, n_3 is 1 and R_6 is $-\text{O}-(\text{CR}_a, \text{R}_b)_{n_7}\text{-L}$, wherein L is




or wherein R_e, R_f taken together with the carbon to which they are attached form a carbonyl group, n_3 is 1 and R_6 is $-O-(CR_a, R_b)n_7-L$, wherein L is



- 5 or wherein R_e, R_f taken together with the carbon to which they are attached form a carbonyl group, n_3 is 1 and R_6 is $-O-(CR_a, R_b)n_7-L$ wherein L is




- 10 7. A compound according to claim 1 of formula II




II

wherein R_c is H; m₁ is 0 or 1; y is 1-3;
Ar₁ and Ar₂ are both




5

8. A compound according to claim 4 of the formula




II

10 wherein Ar₁ and Ar₂ are both




5

9. A compound according to claim 1 of the formula




10 wherein Ar₁ and Ar₂ are both



10. A compound according to claim 1 selected from the group consisting of



15





or any enantiomer thereof,
or a pharmaceutically acceptable salt thereof.


5


11. A compound selected from the group consisting of











or any enantiomer thereof,
or a pharmaceutically acceptable salt thereof.

5

12. A composition comprising a neurokinin antagonistic effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier material.

10

13. A method for inducing neurokinin antagonism which comprises administering a neurokinin antagonistic effective amount of a compound according to claim 1 to a mammal in need thereof.

15

14. A method for treating chronic airway diseases such as asthma and allergies; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, and rheumatoid arthritis; migraine; central nervous system disorders such as depression, psychosis, dementia, and Alzheimer's disease; Down's syndrome; neuropathy; multiple sclerosis; ophthalmic disorders; conjunctivitis; auto immune disorders; graft rejection;
20 systemic lupus erythematosus; GI disorders such as Crohn's disease and ulcerative colitis; disorders of bladder function; circulatory disorders such as angina; Raynaud's disease; coughing and pain, which comprises administering a therapeutically effective amount of a compound according to claim 1.

INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/IB 96/01018

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/12 C07D405/14 C07D409/14 C07D401/14 C07D453/02
C07D487/04 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 655 442 (FUJISAWA PHARMACEUTICAL CO) 31 May 1995 see the whole document ---	1-12
A	GB,A,2 230 262 (SCRAS) 17 October 1990 see the whole document ---	1-12
P,A	WO,A,96 10568 (MERCK & CO INC ;CHIANG YUAN CHING P (US); FINKE PAUL E (US); MACCO) 11 April 1996 see the whole document ---	1-12
A	WO,A,94 13646 (MERCK & CO INC ;MILLS SANDER G (US); BUDHU RICHARD J (US); DORN CO) 23 June 1994 see the whole document --- -/--	1-12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

3 January 1997

Date of mailing of the international search report

1 3. 01. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/IB 96/01018

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO,A,92 20661 (MERCK & CO INC) 26 November 1992 see the whole document -----</p>	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 96/01018

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13,14 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/IB 96/01018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0655442	31-05-95	AU-A- 7911194	08-06-95
		CA-A- 2136712	30-05-95
		CN-A- 1107149	23-08-95
		HU-A- 71348	28-11-95
		JP-A- 7242641	19-09-95
		ZA-A- 9409228	01-08-95
		BR-A- 9500539	31-10-95

GB-A-2230262	17-10-90	AT-B- 399337	25-04-95
		AT-A- 86690	15-09-94
		AU-B- 631334	19-11-92
		AU-A- 5326190	01-11-90
		BE-A- 1007245	02-05-95
		CA-A- 2014521	15-10-90
		CH-A- 681301	26-02-93
		DE-A- 4011925	18-10-90
		FI-B- 92058	15-06-94
		FR-A- 2645743	19-10-90
		FR-A- 2645859	19-10-90
		GR-B- 1000355	25-06-92
		HK-A- 95092	04-12-92
		IE-B- 65058	04-10-95
		IT-B- 1241631	25-01-94
		JP-A- 2292266	03-12-90
		LU-A- 87719	24-07-90
		NL-A- 9000798	01-11-90
		NO-B- 176098	24-10-94
		OA-A- 9446	15-10-92
		PT-B- 93736	30-09-96
		SE-A- 9001269	16-10-90
		US-A- 5019576	28-05-91

WO-A-9610568	11-04-96	AU-A- 3642995	26-04-96

WO-A-9413646	23-06-94	US-A- 5344830	06-09-94
		AU-A- 5603094	04-07-94

WO-A-9220661	26-11-92	US-A- 5292726	08-03-94
